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ABSTRACT 
 
FUNCTIONS OF ATOH8 AND MEKK3 IN CARDIOVASCULAR DEVELOPMENT 
 
David R. Rawnsley 
Mark L. Kahn 
 
The transcription factor ATOH8 and the kinase MEKK3 are evolutionary conserved 
proteins with known expression within the cardiovascular system.  However, the roles of 
these proteins in the developing heart are undefined.  We used a combination of mutant 
mouse models, morpholino gene suppression in the zebrafish, and cell culture to 
determine the role of these two proteins in cardiovascular system.  Our experiments with 
ATOH8 reveal a direct interaction between ATOH8 and the cardiovascular transcription 
factors FOG2 and GATA4.  This interaction is required in vivo in the developing 
zebrafish heart, where Atoh8 functions with Gata and Fog factors to promote proper 
cardiac looping.  However, our genetic studies in the mouse show that ATOH8 is not 
required for cardiovascular development and has a much weaker genetic interaction with 
GATA4 in mammals.  These results identify a novel interaction and role for Atoh8 in the 
zebrafish heart and also definitively exclude a requirement for ATOH8 in mammalian 
development.  Our experiments with MEKK3 reveal a requirement for this protein in 
regulating endocardial growth factors that promote myocardial growth.  We show that 
MEKK3 interacts with CCM2L, an endocardial protein known to regulate growth factor 
production in the endocardium in conjunction with the transmembrane protein HEG.  
 v 
Deletion of MEKK3 in the endocardium leads to embryonic death secondary to decreased 
myocardium, likely due to decreased myocardial proliferation.  MEKK3 genetically 
interacts with HEG in vivo, providing additional evidence for coordinated function 
between MEKK3 and the HEG-CCM complex.  These findings highlight a new role for 
MEKK3 in cardiovascular development and begin to identify the molecular mechanism 
underlying endocardial growth factor support for myocardial growth. 
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Chapter 1: Introduction 
 
Summary 
 This chapter will present an introduction to the two projects discussed in this 
dissertation: 1) my studies on interactions between ATOH8 and GATA4-FOG2 in 
development, and 2) my studies on the regulation of the endocardial growth factors by 
the MEKK3 and the HEG-CCM complex.  As these two projects are unrelated, this 
chapter will be separated into two parts.  In the first half, I will discuss the prior studies 
performed on the transcriptional factor ATOH8.  I will then discuss the known functions 
and interactions of GATA4 and FOG2, two interacting partners of ATOH8, in the heart 
and the lungs.  In the second half of this introduction I will discuss pro-growth signaling 
from the endocardium to the myocardium and also reciprocal signaling from the 
myocardium to the endocardium.  I will briefly discuss cerebral cavernous malformations 
(CCM) and the CCM complex that underlies this disorder.  I will then discuss the 
additional CCM complex proteins that our lab has identified and the role that these 
proteins play in endocardial growth factor signaling. 
 
Introduction: Atoh8 
In vitro and in vivo studies of ATOH8 in vertebrates 
 The gene Atonal homolog 8 (Atoh8) encodes the protein ATOH8, a basic helix-
loop-helix (bHLH) transcription factor.  bHLH factors are defined by the presence of a 
basic-helix-loop-helix domain in which the basic region binds DNA and the helix-loop-
helix region mediates dimerization to a second bHLH protein (1).  Within the hierarchy 
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of bHLH factors, Atoh8 is the sole mammalian member of the Net family (2).  The 
ATOH8 bHLH domain shares 43-57% identity on the amino acid level with the bHLH 
domains of proteins in the Atonal, NeuroD, and Neurogenin families, and the bHLH 
domain is highly conserved across vertebrate ATOH8 homologues (3).  Unlike many 
genes within the atonal superfamily that are encoded by a single exon, Atoh8 has a unique 
three-exon gene structure that is conserved from zebrafish to mammals (4).  The 
conserved gene structure and conserved sequence of the bHLH domain suggest the 
possibility of an evolutionary conserved role for Atoh8 in vertebrates. 
 Several studies have attempted to ascribe functions to ATOH8 through both in 
vitro and in vivo approaches.  The first in vitro study overexpressed ATOH8 by retroviral 
infection in murine retinal explants, which resulted in a decrease in glial cells and an 
increase in rod cells, suggesting that ATOH8 may regulate neuronal-glial fate 
determination (3).  In vitro studies of ATOH8 function in the pancreatic cell lines 
indicate that ATOH8 can physically interact with other bHLH factors, such as 
NEUROG3 and NEUROD1, and can function as a transcriptional repressor of pancreatic 
genes, suggesting a potential role in pancreatic development (5).  Studies of cultured 
human endothelial cells detected an upregulation of the human orthologue ATOH8 in 
response to fluid flow, suggesting that ATOH8 may function in the endothelial response 
to shear stress (6).  All of these studies have been limited by being in vitro rather than in 
vivo approaches, and it remains unclear whether ATOH8 has any required in vivo activity 
in neural, pancreatic, or endothelial development or function. 
 Two studies have attempted to determine the in vivo requirements for ATOH8.  In 
the zebrafish, morpholino gene suppression studies of Atoh8 were performed to 
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determine the requirement in the developing fish (7).  Morphant embryos developed 
severe body plan malformations and died between 24 and 72 hours post fertilization 
(hpf).  Morphant embryos were observed to have impaired somite development, with 
decreased expression of myogenic genes such as myoD and myogenein.   Morphant 
embryos also had a decreased number of neuronal cells in the retina, a finding possibly 
consistent of the role in neural development that had previously been ascribed to murine 
Atoh8 in retinal explant studies (3). 
 A second group attempted to determine the role of Atoh8 in mammals by deriving 
an Atoh8 mutant mouse (5).  This allele has a 10 kb deleted region containing exon 1, 
exon 2, and the intervening intron 1; exons 1 and 2 contain nearly all of the Atoh8 coding 
sequence.  Mice homozygous for this allele were found to be dead by E8.5 and reportedly 
appeared to have arrested shortly after gastrulation. This early lethality has precluded the 
use of these mice in studying the developmental or postnatal requirement for ATOH8, 
and the role for this gene in mammals has remained ambiguous. 
 
GATA4 and FOG2 in heart and lung development 
 The GATA transcription factor family regulates the development of multiple 
organ systems in vertebrates.  GATA factors are characterized by binding to the DNA 
binding motif WGATAR and by structural conservation of two zinc fingers (8).  Among 
the six vertebrate GATA factors, GATA4, GATA5, and GATA6 regulate multiple steps 
in the development of the vertebrate heart, as well as several reproductive and 
endodermal tissues (9-11).  Although these factors are partially redundant (12,13), 
GATA4 has been identified as a critical factor in cardiovascular development. GATA4-/- 
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embryos develop cardia bifida and die by E9.5 (14,15), and both endothelial and 
myocardial-specific Gata4 deletions exhibit lethal embryonic cardiac defects (16,17).  
Gata4 heterozygosity is sufficient to cause cardiac defects on certain genetic background, 
as shown by Gata4+/- mice that develop septal defects and ventricular hypoplasia when 
bred into a C57BL/6 background (18,19).  Familial congenital heart defects have also 
been linked to GATA4 heterozygosity, demonstrating that conservation of GATA4’s 
critical role in the heart extends to humans (19-21).  The cardiac requirement for GATA4 
also extends to the developing zebrafish heart.  Although gata5 appears to the most 
critical GATA factor in the zebrafish cardiogenesis (22), morpholino gene suppression of 
Gata4 results in an unlooped heart tube (23), indicating that GATA4 has a conserved 
requirement in heart development that extends from fish to mammals. 
 GATA4 does not operate in isolation in cardiac development and has been shown 
to interact with other cardiac transcription factors (e.g. Tbx5 (20)).  Among these 
interactions, the best characterized is that between GATA4 and FOG2, a member of the 
Friend-of-GATA (FOG) family of transcriptional regulators (24,25).  FOG proteins are 
unable to bind DNA and must instead bind GATA factors in order to regulate 
transcription (26).  GATA factors bind FOG proteins via a highly conserved sequence on 
the N-terminal GATA zinc finger, and a Gata4 point mutation that disrupts this 
interaction in vivo phenocopies the loss of FOG2 (26,27).  Thus, the major developmental 
role of FOG2 is dependent on binding to GATA4.   Interactions with FOG factors have 
been shown to exert both positive and negative effects on GATA transcriptional activity 
that depend on the cellular context (24,28-30).   FOG proteins play critical roles in heart 
development in multiple vertebrate species.  In the mouse, loss of FOG2 results in cardiac 
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defects and embryonic death (31-33).  In the zebrafish, loss of Fog1, the Fog factor 
expressed in the heart, results in a failure of heart looping (34).  Like GATA4, mutations 
in FOG2 have been linked to human congenital heart disease (35), making further study 
of GATA-FOG function and identification of additional GATA-FOG interacting partners 
an important goal for understanding human disease. 
 In addition to their roles in heart development, FOG2 and GATA4 have additional 
roles in the developing lung.  A forward genetic screen in mice identified a point 
mutation in Fog2 that results in disrupted diaphragmatic development and pulmonary 
hypoplasia that was particularly severe in the accessory and right medial lobes (36).  This 
pulmonary role for FOG2 has also been observed in human patients, where FOG2 point 
mutations have been linked to neonatal death from pulmonary aplasia and congenital 
diaphragmatic hernia (36).  Given FOG2’s dependence on a GATA factor for 
transcriptional function, subsequent studies in the lung attempted to identify the GATA 
partners of FOG2.  Examination of lungs from mice homozygous for either Gata4 or 
Gata6 point mutant alleles that could not bind FOG2 revealed that the GATA4-FOG2 
interaction was critical for proper lung development (37), whereas the GATA6-FOG2 
interaction was not required.  In line with this observation, Gata4 and Fog2 expression in 
the pulmonary system is limited to the mesenchyme of the developing lung (36), whereas 
Gata6 expression is much more extensive (18,38).  These results suggest a specific role 
for the GATA4-FOG2 complex in pulmonary mesenchyme development, although there 
is no evidence regarding which targets GATA4 and FOG2 regulate in the mesenchyme or 
what other interacting partners they may have in this tissue.  
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Conclusions and Outstanding Questions 
 ATOH8 is a transcription factor with a bHLH domain that is highly conserved 
across vertebrate species.  This sequence conservation suggests a conserved requirement 
for ATOH8 in these species.  Although several reports have attempted to ascribe 
functions to ATOH8, these studies have been limited by the flaws of the current in vivo 
loss-of-function models.  The zebrafish morpholino experiments provide evidence for a 
requirement for Atoh8 in muscle and retinal development.  However, the severe structural 
defects in these embryos may mask more subtle phenotypes, and using lower doses of the 
morpholinos may identify additional requirements for Atoh8.  In the mouse, the early 
embryonic death of the reported mutant mouse at gastrulation prevents any definitive 
determination of the required roles for Atoh8 in mammals.  To further study Atoh8, 
additional mutant mouse models are required, particularly conditional alleles that will 
allow us to bypass early lethality and enable us to derive tissue-specific deletions to 
determine where and when Atoh8 is acting. 
 In the case of GATA4 and FOG2, the role of these proteins has been extensively 
studied in the heart.  However, it remains unclear what controls FOG2 binding to 
GATA4—when does GATA4 bind FOG2, and when it is independent of FOG2?  One 
possibility is that other transcription factors may modulate FOG2-GATA4 binding and 
promote or inhibit formation of FOG2-GATA4 complexes at different sites throughout 
the genome.  It would therefore be interesting to identify transcription factors that are 
capable of physically interacting with GATA4-FOG2 and also capable of functionally 
interacting with these proteins in vivo. 
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Introduction: CCM, MEKK3, and Endocardial Growth Factors  
Endocardial-myocardial signaling 
 The inner wall of the myocardium of the heart is lined by endocardium, a 
specialized form of endothelium.  In addition to performing the traditional roles of 
endothelium, such as separating circulating blood cells from cardiomyocytes and 
inhibiting inappropriate activation of coagulation, the endocardium also produces 
multiple growth factors that promote cardiomyocyte survival, proliferation, and 
maturation.  Concurrently with these endocardial signals, the myocardium produces 
signals promoting endocardial development, creating a signaling cross talk that is 
necessary for the development of both cell types within the heart. 
 Previous studies have identified the protein neuregulin and FGF factors as critical 
endocardial growth factors.  Neuregulin is a member of the epidermal growth factor 
(EGF) family; endocardial neuregulin activates the myocardial receptors ErbB2 and 
ErbB4 to promote cardiomyocyte survival and proliferation, and ventricular trabeculation 
(39,40).  Null mutations of neuregulin or its receptors lead to reduced myocardial 
proliferation, decreased ventricular trabeculation, and embryonic death by E10.5 (41-43).  
Similar findings have been observed with endocardial fibroblast growth factors (FGF) 
and their associated FGF receptors (FGFR) in the myocardium.  FGF9, FGF16, and 
FGF20 are expressed from the endocardium during cardiac development and activate the 
receptors Fgfr1 and Fgfr2 in the myocardium (44).   FGF9-/- and FGF16-/- embryos both 
exhibit reduced myocardial proliferation (44,45); similar myocardial phenotypes are seen 
in mice lacking Fgfr1 and Fgfr2 in cardiomyocytes (44).  It is unknown, however, what 
signals drive endocardial neuregulin and FGF production. 
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 Reciprocal myocardial signals to the endocardium include vascular endothelial 
growth factor (VEGF) and angiopoietin-1 (ANG1).  Myocardial VEGF, while not 
required for endocardium survival, promotes induction of endocardial cells into 
endothelial cells to form coronary arteries (46).  Mice lacking myocardial ANG1 have a 
thin myocardium and fail to develop ventricular trabeculations (47).  As ANG1 activates 
receptors on the endocardium, this result suggests that ANG1 promotes production of 
endocardial growth factors that then facilitate myocardial growth and development, 
although it is unknown what pathways ANG1 would activate in the endocardial cell to 
drive growth factor production. 
 While multiple endocardial-to-myocardial growth factor pathways have been 
identified, little is known about what regulates these pathways within the endocardium.  
Prior work in our lab has identified the HEG-CCM pathway as a novel regulator of 
endocardial growth factor production. 
 
CCM Signaling and Endocardial Growth Factors 
 Cerebral cavernous malformations (CCM) are vascular lesions that develop 
within the vasculature of the central nervous system (CNS) and predispose patients to 
hemorrhagic stroke and focal neurological deficits (48).  CCM lesions can either occur 
sporadically or occur as an inherited familial disorder.  Patients with familial CCM 
lesions are heterozygous for CCM1, CCM2, or CCM3.  CCM lesions form when a loss of 
heterozygosity occurs within the endothelium of the CNS (49-51); CCM lesions caused 
by mutations in any of the three genes are clinically indistinguishable, indicating that 
CCM1, CCM2, and CCM3 likely operate in a common pathway (48).  In support of this 
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conclusion, biochemical studies have demonstrated that CCM1, CCM2, and CCM3 form 
a complex where CCM1 binds CCM2, which then binds CCM3 (52).  Mice deficient for 
CCM1, CCM2, or CCM3 develop early lethal embryonic vascular defects (53-55), 
indicating that these proteins have a role in cardiovascular development in addition to 
their known role in CCM disease pathogenesis. 
 Previous work in our lab identified two additional components of the CCM 
complex: Heart-of-glass (HEG) and cerebral cavernous malformation 2-like (CCM2L).  
HEG is a transmembrane protein that can interact with the CCM complex by binding 
CCM1 (52).  Loss of the zebrafish homologue Heg has been reported to result in 
defective myocardial growth (56), phenocopying the loss of CCM1 and CCM2 in the 
zebrafish (57) and linking Heg to the CCM complex.  In the mouse, loss of Heg results in 
death in approximately half of animals in late embryogenesis or early postnatal life from 
either hemorrhages within the pulmonary vasculature or from myocardial ruptures 
secondary to local patches of thin myocardium (52).  Our lab has also identified CCM2L, 
a paralogue of CCM2 that retains CCM2’s ability to bind CCM1 but cannot interact with 
CCM3 (58).  Ccm2l-/- mice are viable without overt defects; however, Heg-/- Ccm2l-/- 
double mutant mice are lethal by E10.5 from heart failure secondary to reduced 
myocardial proliferation (58).  Expression of CCM2L and HEG at this time point is 
limited to the endocardium, indicating that the myocardial defects were due to a depletion 
of endocardial growth factors.  Levels of FGF16 mRNA, a critical endocardial-to-
myocardial growth factor (45,59), were found to be reduced in Heg-/- Ccm2l-/- hearts, 
indicating that endocardial HEG and CCM2L are required to generate FGF16 and 
promote myocardial growth. 
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Conclusions and Outstanding Questions 
 The past studies on HEG have revealed a role for this endocardial protein in 
regulating myocardial growth (52,56).  This role has become much clearer with the recent 
report of the Heg-/- Ccm2l-/- double mutant mouse that dies by E10.5 from heart failure 
secondary to profound myocardial thinning (58).  These mice have decreased FGF16 
levels in their hearts, identifying the likely target of HEG and CCM2L and also 
identifying the mechanism through which myocardial growth is stimulated. 
 The central outstanding question of this project is identifying the mechanism 
through which HEG and CCM2L regulate growth factor production.   HEG is localized to 
the membrane due to its transmembrane domain, and CCM2L is mostly localized near the 
membrane due to its interaction with CCM1 and CCM1’s interaction with HEG.  As 
neither of these proteins have transcriptional function, there is no mechanism through 
which they could directly alter FGF16 transcription.  We conclude that there must an 
associated pathway, likely binding CCM2L, that is modulating FGF16 transcription. 
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Chapter 2: ATOH8 regulates GATA4 and FOG2 during Vertebrate Development 
 
The data in this Chapter have been published in the Journal of Biological Chemistry (60).  
 
Summary 
 Atonal homolog 8 (Atoh8) is a bHLH transcription factor that is highly conserved 
in vertebrates.  Here we show that zebrafish atoh8 is required for heart tube looping and 
swimbladder inflation, and that atoh8 specifically interacts with gata4 and zfpm1 (Fog1) 
in these developing tissues.  We used co-immunoprecipitation studies to show that 
ATOH8 can form a physical complex with GATA4 and FOG2, suggesting a molecular 
mechanism explaining the genetic interaction in the zebrafish.  In contrast to the role of 
atoh8 in the zebrafish, multiple Atoh8 mutant mouse mice models exhibit normal cardiac 
development, indicating that the cardiac function of Atoh8 is not required in the mouse.  
We showed there is increased early postnatal death in Gata4+/- Atoh8GFP/GFP mice, 
suggesting that genetic interaction between Gata4 and Atoh8 is conserved into mice.  We 
were unable to detect structural or functional defect in the hearts or lungs of these mice, 
however, preventing us from determining the cause of death or site of GATA4-ATOH8 
interaction in these mice.   
 
Introduction 
 The gene Atonal homolog 8 (Atoh8) encodes the protein ATOH8, a basic helix-
loop-helix (bHLH) transcription factor within the atonal superfamily.  The sequence of 
the ATOH8 bHLH domain is highly conserved across vertebrate ATOH8 homologues 
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(3), and Atoh8 has a unique three-exon gene structure that is conserved from zebrafish to 
mammals and that is unique among bHLH factors in the atonal superfamily(4).  The 
conserved gene structure and conserved sequence of the bHLH domain suggest the 
possibility of an evolutionary conserved role for Atoh8 in vertebrates. 
 As we previously discussed in Chapter 1, limited in vitro and in vivo studies have 
several potential functions for Atoh8.  Morpholino knockdown of atoh8 in the zebrafish 
was reported to lead to severe developmental malformations and early embryonic death, 
in addition to specific defects in development of the somites and retina (7).  The early 
death and severe defects seen in the atoh8 morphant embryos may mask more subtle 
defects in other aspects of zebrafish development; lower doses of morpholinos may 
bypass these early phenotypes and allow us to analyze the role of atoh8 in later 
embryonic stages. 
 In contrast to the zebrafish, the in vivo requirement for Atoh8 in mammals has 
remained elusive.  One group has reported creation of an Atoh8 mutant allele with a 
deletion of exon1, intron 1, and exon 2 (hereafter referred to as the Atoh8Δex1-2 allele) (5).  
Atoh8Δex1-2/Δex1-2 mice were reported to be lethal by E8.5 and to be arrested at gastrulation.  
This early lethality precluded further use of these mice in studying the developmental or 
postnatal requirement for ATOH8 in specific tissues. 
  Prior to the publication of the lethal Atoh8Δex1-2 mouse and prior to the start of my 
thesis project, our lab attempted to create an Atoh8 mutant mouse.  The coding sequence 
of eGFP followed by a stop codon was inserted into the first exon, replacing the N-
terminus of the Atoh8 sequence and creating the Atoh8GFP allele.  Mice homozygous for 
this allele were viable on a C57BL/6-129/Sv mixed background, but exhibited runting 
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that developed by weaning and persisted into adulthood.  When these mice were bred 
onto a pure C57BL/6 background, approximately 50% of the Atoh8GFP/GFP mice died 
between birth and weaning (data not shown).  These results strongly contradicted the 
phenotype of the Atoh8Δex1-2/Δex1-2 mouse, which was completely lethal prior to E8.5 (5).  
We interpreted this discrepancy as likely being due to the degree of deletion in these two 
alleles, with the Atoh8Δex1-2 allele deleting multiple exons and the Atoh8GFP allele deleting 
only a portion of Atoh8 exon 1.  Two different hypotheses appeared possible from this 
result.  First, the Atoh8Δex1-2 allele could be a complete Atoh8 null allele and the Atoh8GFP 
allele could be a hypomorphic allele.  In this interpretation, total loss of Atoh8 in 
Atoh8Δex1-2/Δex1-2 mice leads to early embryonic lethality, whereas partial Atoh8 function in 
Atoh8GFP/GFP mice leads to runting and strain-dependent partial postnatal lethality.  
Alternatively, the Atoh8GFP/GFP could be a true Atoh8 null allele, and Atoh8Δex1-2/Δex1-2 
mice could have an additional defect unrelated to loss of ATOH8 protein that resulted in 
its early embryonic lethality. 
 We hypothesized that ATOH8 had conserved and required functions in vertebrate 
development.  In order to test this hypothesis, we took two separate approaches to 
examine in vivo ATOH8 function.  First, we used morpholinos to knockdown atoh8 in 
zebrafish embryos to identify additional in vivo requirements for atoh8.  Secondly, in 
order to identity the functions of Atoh8 in mammals, we generated and characterized 
additional Atoh8 mutant mice models to definitely resolve the discordant phenotypes 
between Atoh8Δex1-2/Δex1-2 and Atoh8GFP/GFP mice and to determine the requirement for 
Atoh8 in mammalian development. 
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Results 
atoh8 is required for zebrafish heart looping and swim bladder development 
 There is a high degree of conservation between the mouse gene Atoh8 and the 
zebrafish homolog atoh8 (3), suggesting that there may be a conserved function for this 
gene across vertebrate species.  Knockdown of atoh8 by morpholino in the zebrafish has 
previously been reported to result in severe developmental malformations in skeletal 
muscle somites and in the retina and death by 72 hpf (7).  We hypothesized that lower 
morpholino doses would reveal additional developmental roles for atoh8.  We used the 
same translation-blocking morpholino, atoh8-MO1, as Yao et al and lowered the injected 
dose to 2.5 ng per embryo.  At this dose embryos did not develop the retinal and skeletal 
muscle defects seen at higher doses and greater than 90% of embryos survived beyond 72 
hpf.  Approximately 75% of embryos injected with atoh8-MO1 at a 2.5 ng dose 
developed an unlooped heart tube and pericardial edema by 72 hpf (Figure 2.1.A-F).  We 
attempted to rescue this phenotype with atoh8 cRNA injection, but we were unable to 
rescue due to toxicity of the cRNA by 72 hpf (data not shown).  To confirm that this heart 
phenotype was due to loss of atoh8, we injected two additional atoh8 morpholinos—one 
targeting the splice donor site at the exon 1/intron 1 junction (atoh8-MO2) and an 
additional translation-blocking morpholino targeting the 5’UTR (atoh8-MO3).  Each 
morpholino produced a similar heart tube looping defect (Figure 2.1.G-H).   In contrast, 
an atoh8-MO1 morpholino with five point mutations failed to induce a heart looping 
defect (data not shown).  To further test the specificity of the observed cardiac defects in 
atoh8 knockdown zebrafish we lowered the doses of all three atoh8 morpholinos and 
used them individually and in combination.  At low doses single morpholinos induced 
 15 
heart looping defects in less than 10% of embryos; when used in combination greater 
than 90% of embryos developed an unlooped heart (Figure 2.1.I).  This synergy suggests 
that the heart phenotype is due to knockdown of the same target gene by all three 
morpholinos, indicating that this phenotype is due to specific loss of atoh8.  These results 
indicate that atoh8 is required for normal cardiac looping in zebrafish. 
 Morpholino knockdown of atoh8 also revealed that 95% of injected embryos 
failed to develop an inflated swimbladder by 96 hpf (Figure 2.2.A-C).  This swimbladder 
phenotype was observed in embryos with the heart phenotype (Figure 2.2.B) as well as 
embryos without the phenotype (Figure 2.2.C), indicating that the swimbladder defect is 
highly penetrant and independent of the cardiac defect. 
 
Atoh8 interacts specifically with Gata4 and Zfpm1 in the developing zebrafish heart 
 In order to identify candidate genes and pathways that interact with atoh8, we 
looked for genes that exhibit similar heart and swimbladder defects in response to 
morpholino knockdown.  Knockdown of gata4 results in an unlooped heart, pericardial 
edema, and an uninflated swimbladder (23).  To determine whether a genetic interaction 
exists between atoh8 and gata4, we injected zebrafish embryos with low dose gata4-
specific and atoh8-specific morpholinos individually and in combination.  Embryos were 
then scored to determine the penetrance of swimbladder and heart phenotypes to detect 
genetic interaction between atoh8 and gata4 (61,62).  Co-injection of atoh8 and gata4 
morpholinos resulted in a synergistic increase in the penetrance of both the swimbladder 
(Figure 2.3.A) and heart (Figure 2.3.B) phenotypes.  These results suggest that atoh8 
interacts with gata4 in the developing zebrafish swimbladder and heart. 
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 GATA factors are critical members in the transcriptional network controlling 
vertebrate heart development (10).  Within this transcriptional network, atoh8 may 
interact specifically with gata4, or it may genetically interact with multiple cardiac 
transcription factors.  In order to determine the specificity of the atoh8-gata4 interaction, 
we examined whether atoh8 exhibited genetic interaction with other transcription factors.   
Heart looping defects in the zebrafish have been previously observed with morpholino 
knockdown of mef2ca (61), tbx-5a (63), and zfpm1 (encoding Fog1) (34).  Small additive 
increases in the penetrance of the unlooped heart phenotype were observed when mef2ca 
(Figure 2.3.C) or tbx-5a (Figure 2.3.D) morpholinos were injected in combination with 
atoh8-MO1. In contrast, a larger synergistic increase was observed with co-injection of 
zfpm1 and atoh8 morpholinos (Figure 2.3.E).  These results suggest that atoh8 
specifically interacts with gata4 and zfpm1 in the developing zebrafish heart. 
 gata4 and zfpm1 encode Gata4 and Fog1 proteins respectively.  Previous studies 
have revealed a physical interaction between mouse GATA4 and FOG2 (28), and 
germline expression of a GATA4 point mutant that does not bind FOG2 phenocopies the 
loss of FOG2 and leads to cardiovascular death in mice (27).  Thus the interaction 
between GATA and FOG factors is critical for heart development.  To determine if a 
similar genetic interaction exists between gata4 and zfpm1 in the zebrafish, we co-
injected low doses of the gata4 and zfpm1 morpholinos. gata4-zfpm1 morpholino 
combinations conferred an increased penetrance of the heart looping defect to a degree 
similar to that observed with atoh8-gata4 and atoh8-zfpm1 morpholino combinations 
(Figure 2.3.F), suggesting that Gata4 and Fog1 also interact in the developing zebrafish 
heart 
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 Our results suggested that atoh8 might act in concert with both gata4 and zfpm1.  
To further test this hypothesis, morpholino doses were lowered further and combinatorial 
knockdown studies performed.  At doses in which each individual morpholino induced 
heart looping in <5% of embryos (Figure 2.3.G), injection of all three morpholinos 
resulted in heart looping defects in approximately 90% of embryos (Figure 2.3.G).  This 
powerful synergy between the three transcription factors suggests a strong interaction 
between atoh8, gata4, and zfpm1 in the developing zebrafish heart.  
 
ATOH8 forms a biochemical complex with GATA4 and FOG2 
 The strong genetic interaction observed between atoh8, gata4 and zfpm1 in the 
developing zebrafish suggested either that Atoh8 functions upstream or downstream of 
the Gata-Fog complex in a common genetic pathway (i.e. an epistatic relationship) or that 
these 3 transcription factors function together in a single complex (i.e. a biochemical 
relationship).  qPCR studies of fish embryos injected with atoh8 morpholinos failed to 
reveal changes in the expression levels of either gata4 of zfpm1 and morpholino 
knockdown of gata4 of zfpm1 did not alter atoh8 levels (data not shown), suggesting that 
atoh8 does not interact with gata4 and fog1 epistatically.  To assess a direct, physical 
interaction between these transcription factors epitope-tagged mouse ATOH8, GATA4 
and FOG2 proteins were co-expressed in HEK293T cells and a series of co-
immunoprecipitation experiments performed.  We were unable to immunopreciptiate 
FLAG-ATOH8 and V5-GATA4 together (Figure 2.4.A).  However, immunoprecipitation 
of FLAG-ATOH8 was associated with co-immunoprecipitation of V5-FOG2 (Figure 
2.4.A), and when all three proteins were co-expressed V5-GATA4 could be pulled down 
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with both FLAG-ATOH8 and V5-FOG2 (Figure 2.4.B).   Finally, co-expression of 
FLAG-ATOH8, V5-FOG2 and V5-GATA4-V217G, a GATA4 point mutant that has 
been shown to be unable to associate with FOG2 (27), confirmed that association of 
GATA4 with ATOH8 is bridged by FOG2 (Figure 2.4.B).   We attempted to confirm the 
ATOH8-FOG2 interaction and assess a direct mechanism of interaction using GST-
ATOH8 and GST-FOG2 fusion protein binding assays, but we were unable to generate 
the GST-FOG2 protein (perhaps due to the large size of FOG2) (data not shown).  These 
studies provided a biochemical explanation for the genetic interaction observed between 
atoh8, gata4, and zfpm1 in the fish, and suggested that a similar relationship should exist 
in the mouse. 
 
atoh8 is weakly expressed in the zebrafish heart tube 
 Our co-immunopreciptiation experiments suggested that physical interaction 
underlies the genetic interaction observed between atoh8, gata4 and zfpm1.  Based on 
this finding, we hypothesized that atoh8 is expressed in the zebrafish heart tube with 
gata4 and zfpm1.  In situ hybridization revealed atoh8 expression throughout the embryo 
at 13 hpf (Figure 2.5.A-B), 30 hpf (Figure 2.5.C-D) and 48 hpf (Figure 2.5.F), consistent 
with a previous report of atoh8 expression (7).  Weak atoh8 expression was observed in 
the heart tube at 30 hpf (Fig. 5C-D), overlapping with the cardiac expression of gata4 
(Figure 2.5.E) and with the reported expression of zfpm1 (34).  This expression data is 
consistent with our hypothesis that a physical complex between the proteins Atoh8, 
Gata4, and Fog1 in the zebrafish, and suggests this could be the molecular mechanism 
underlying the genetic interaction we observe in the developing zebrafish. 
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Atoh8 is not required for survival in the mouse 
 In order to determine the requirement for ATOH8 in the mouse, previous 
members of our lab had created and begun to characterize an Atoh8 mutant mouse.  The 
eGFP coding sequence followed by a stop codon was inserted into exon 1 to generate the 
Atoh8GFP allele (Figure 2.6.A); approximately 50% of the coding region of exon 1 was 
deleted in this allele.  On a mixed genetic background, Atoh8GFP/GFP mice were reported 
to be viable but runted; when backcrossed onto a C57BL/6 genetic background, 
approximately half of Atoh8GFP/GFP mice were reported to die prior to weaning (data not 
shown).   This phenotype differed significantly from a published report of an Atoh8 
mutant mouse from another lab (5).  This group used recombination with a bacterial 
artificial chromosome (BAC) targeting vector to delete a 10 kilobase region of Atoh8, 
replacing exon 1, intron 1, and exon 2 with sequence for an eGFP-Cre fusion protein (the 
Atoh8Δex1-2 allele).  Mice homozygous for this Atoh8Δex1-2 allele were reported to be lethal 
shortly after gastrulation, precluding use of these mice to determine the function of Atoh8 
in cardiac development. 
 Due to the discrepant phenotypes between these Atoh8GFP and Atoh8Δex1-2 mutant 
models, we hypothesized that the Atoh8GFP allele may be a hypomorphic allele with 
residual function.  In order to create a definitive deletion of exon 1 of Atoh8, we designed 
a mutant allele deleting all of exon 1 of Atoh8 (Figure 2.7.A).  The 5’ loxP site was 
placed 617 base pairs upstream of the transcriptional start site; this position places the 
loxP outside a conserved region of sequence upstream of the Atoh8 transcribed region 
that we suspected contain conserved regulatory elements and the Atoh8 promoter.  The 3’ 
loxP was placed in intron 1.  Recombination between these sites deletes exon 1 and the 
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putative Atoh8 promoter.  Atoh8fl/fl mice were viable with no apparent defects.  
Transgenic mice expressing CMV-Cre (64) were used to recombine the Atoh8fl allele in 
the mouse germline cells and create the Atoh8Δex1 allele (Figure 2.7.A).  Atoh8Δex1/Δex1 
mice were viable at the expected Mendelian ratio at postnatal day 14 on a mixed genetic 
background (Table 2.1) and did not display any overt phenotypes into adulthood.  
Atoh8Δex1/Δex1 mice also failed to exhibit the runting previously reported Atoh8GFP/GFP 
mice, suggesting that the previous characterization of the Atoh8GFP/GFP mouse was 
incorrect.  At this point, we attempted to reproduce the previous data showing postnatal 
death in Atoh8GFP/GFP mice on a C57BL/6 background.  We were unable to reproduce this 
data, as Atoh8GFP/GFP mice were found at Mendelian ratios (Table 2.2) and exhibited no 
overt phenotypes.  In summary, two different mutant alleles of Atoh8 exon 1 
(Atoh8Δex1/Δex1 and Atoh8GFP/GFP) do not affect viability and indicate that Atoh8 exon 1 is 
not required for survival in the mouse. 
 Although our Atoh8Δex1 allele removed exon 1 and the putative promoter of Atoh8, 
we were able to detect continued expression of Atoh8 exon 2 and 3 mRNA transcript in 
Atoh8Δex1/Δex1 mice by RT-PCR, suggesting that alternative transcripts exist for Atoh8.  In 
order to characterize these transcripts, we performed 5’ Rapid Amplification of cDNA 
Ends (5’RACE) on mRNA isolated from Atoh8Δex1/Δex1 mice (data not shown).  Using 
primers in Atoh8 exon 2, we identified an alternative exon in intron 1 that spliced into 
exon 2 and 3.  There were no open reading frames in this transcript, however, indicating 
that this transcript could not encode any truncated ATOH8 protein.    
 Although we were unable to identify any open reading frames in our Atoh8Δex1/Δex1 
mice, it is possible that our 5’RACE experiments failed to identify all alternative 
 21 
transcripts.  We hypothesized that, in Atoh8Δex1/Δex1 mice, such transcripts could splice 
into the intact exon 2 and possibly create an open reading frame and a partially functional 
ATOH8-like protein.  This hypothesis would potentially explain the difference in 
phenotype between our Atoh8Δex1/Δex1 mouse and the previously published Atoh8Δex1-2/Δex1-2 
mouse that lacks both exon 1 and exon 2.  To test this hypothesis and definitively address 
the role of Atoh8 exon 2, we replaced exon 2 with an IRES-LacZ gene trap cassette to 
generate the Atoh8 LacZΔex2 allele (Figure 2.8.A).  Atoh8 LacZΔex2/LacZΔex2 mice were viable 
and present at the expected Mendelian ratio at postnatal day 14 (Table 2.3).  These results 
indicate that exon 2 of Atoh8 is not required for survival in the mouse.  Since exons 1 and 
2 encode virtually the entire coding sequence of Atoh8, these results indicate that the 
ATOH8 protein is not required in the mouse for survival, and that the embryonic lethality 
of Atoh8Δex1-2/Δex1-2 mice does not reflect a requirement for ATOH8 protein during mouse 
development but instead may reflect loss or alteration of another region due to the use of 
a BAC targeting construct. 
 
Atoh8 expression is restricted to the atria, lung mesenchyme, and vascular smooth 
muscle in the mouse 
 In order to identify possible functions for Atoh8 in the mouse, we determined the 
expression pattern of Atoh8.  Due to the cardiac phenotype we identified in the atoh8 
morphant fish, we first focused on Atoh8 expression in the heart.  Previous studies have 
reported cardiac expression of Atoh8 (3,5,65), but these studies have not defined the 
precise spatial or temporal expression pattern of Atoh8 within the heart.  In order to 
determine the expression pattern of Atoh8, we generated antibodies against an N-terminal 
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fragment of the ATOH8 protein.  These antibodies were able to detect ATOH8 when 
overexpressed in cell culture but could not detect ATOH8 in mouse tissues using 
immunohistochemical staining (data not shown), and we were unable to use them to 
determine Atoh8 expression in vivo. 
 In lieu of an effective antibody, we used the Atoh8LacZ∆ex2 IRES-LacZ gene trap 
allele as a reporter for Atoh8 expression.  Whole mount X-gal staining of Atoh8LacZ∆ex2/+ 
embryos at embryonic day 9.5 (E9.5) revealed LacZ expression in the developing brain, 
eye, somites, limb bud and branchial arches, while the heart was free of LacZ expression 
(Figure 2.9.A).  This pattern was largely maintained at E12.5, with persistent LacZ 
expression in somites, brain, eye, and limb bud (Figure 2.9.B), but no expression in the 
developing heart or liver was detected (Figure 2.9.C).  To determine whether Atoh8 is 
expressed in later stages of heart development, we performed whole mount X-gal staining 
on isolated Atoh8LacZ∆ex2/+ hearts (Figure 2.9.D).  At E16.5, strong LacZ expression was 
observed in both the aorta and pulmonary artery.  There was weak staining of both the 
left and right atria; the ventricles were negative except for the developing coronary 
vessels.  At postnatal day 1 (P1) strong expression in the aorta and pulmonary artery 
persisted, with increased expression in the coronaries and atria, and no staining of the 
ventricles.  The vascular pattern in the great vessels and coronaries was maintained at 
P14.  However, the atrial pattern was altered, with continued right atrial expression but an 
absence of expression in the left atrium.   Whole mount X-gal staining of Atoh8LacZ∆ex2/+ 
organs also revealed strong expression throughout the lung at both E16.5 and P1 (Figure 
2.9.E). 
 In order to determine which cells express Atoh8 in the heart, we next used 
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immunohistochemistry to detect GFP expression from the Atoh8Δex1-2 nuclear GFP 
reporter allele (5).  As was seen with whole mount LacZ staining of Atoh8LacZΔex2/+ mice, 
nuclear GFP expression was detected throughout the atrial myocardium at E16.5 (Figure 
2.9.H-I).  In contrast to whole mount LacZ staining, GFP expression in the atria could 
also be detected at the earlier E12.5 time point (Figure 2.9.F-G), likely due to the higher 
sensitivity of detection for this reporter.  At both time points, the ventricles displayed 
weaker expression than the atria (Fig. Figure 2.9.G, J).  In the ventricles, nuclear GFP 
expression was limited to the layers of cardiomyocytes in closest proximity to the 
endocardium (Figure 2.9.J).  These results indicate that cardiac expression of Atoh8 is 
primarily limited to the atria. 
 We next used the Atoh8Δex1-2/+ GFP reporter allele to further define the Atoh8 
expression pattern in the lung and vasculature.  The GFP reporter showed strong 
expression throughout the mesenchyme of the lung at E12.5 (Figure 2.9.K-L).  In 
contrast, the epithelium was completely devoid of GFP expression at E12.5 (Figure 
2.9.L).  This pattern of expression was preserved at E16.5, with strong mesenchymal 
expression and no expression in the epithelium of either the proximal or distal airways 
(Figure 2.9.M-N). 
 Atoh8Δex1-2/+ GFP expression was observed in the vascular smooth muscle of the 
aorta and pulmonary artery (Figure 2.9.O-R), and in the smaller arteries of the lung 
(Figure 2.9.T).  The endothelium of these vessels was noticeably free of GFP expression 
(Figure 2.9.Q), indicating that vascular Atoh8 expression is limited to the smooth muscle.  
As in ventricular myocardium, GFP expression appeared to be strongest in the smooth 
muscle cells directly underlying the endothelium (Figure 2.9.P-Q), suggesting that 
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muscle cell Atoh8 expression may be regulated in some way by the endothelium.  In 
contrast to the arterial expression pattern, the pulmonary veins were largely free of GFP 
expression (Figure 2.9.S).  Thus studies of the Atoh8LacZ∆ex2 LacZ and Atoh8Δex1-2/+ GFP 
reporter alleles are consistent and demonstrate that Atoh8 is specifically expressed in the 
atria of the heart, lung mesenchyme, and arterial vascular smooth muscle.  These findings 
suggest that restricted gene expression in the mouse may explain the lack of an important 
role for Atoh8 in mouse heart development. 
 
Atoh8 interacts weakly with Gata4 in the mouse 
 Although our results indicated that there is not an absolute requirement for 
ATOH8 in the mouse, our studies in zebrafish embryos and our biochemical studies 
suggested that ATOH8 might be necessary for optimal GATA4 and/or FOG2 function in 
mice.  Loss of Gata4 or Zfpm2 (encoding FOG2) in the mouse leads to severe 
cardiovascular defects and death at E9.5-10.5 and E13.5 respectively (14,15,31).  To test 
for genetic interaction between Atoh8 and Gata4 or Zfpm2 we generated Zfpm2+/-
Atoh8GFP/GFP and Gata4+/-Atoh8GFP/GFP animals. Zfpm2+/-Atoh8GFP/GFP animals were 
viable and present at expected Mendelian ratios at both postnatal day 1 (P1) and postnatal 
day 14 (P14) (Table 2.4).  In contrast, a small decrease in the number of Gata4+/-
Atoh8GFP/GFP animals was observed at P1, and this deficit became more pronounced by 
P14 (Table 2.5).  Gata4+/-Atoh8GFP/GFP mice that survived past P14 were 
indistinguishable from littermates and displayed no overt phenotypes, indicating that 
death occurs in both the immediate neonatal (by P1) and early postnatal (P1-P14) periods.   
 The partial loss of Gata4+/-Atoh8GFP/GFP mice observed at P1 is consistent with 
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either embryonic or neonatal death.  To more precisely determine the time of death, we 
examined embryos in late embryogenesis to determine viability of the Gata4+/-
Atoh8GFP/GFP animals in utero.  In contrast to P1, there was no loss of Gata4+/-
Atoh8GFP/GFP embryos at embryonic day 17.5 (E17.5) relative to control littermates 
(Table 2.6).  These results indicate that loss of Gata4+/-Atoh8GFP/GFP mice occurs between 
E17.5 and P1. These results reveal that although ATOH8 is not essential for mouse 
development, genetic interaction between Gata4 and Atoh8 is conserved from zebrafish 
to mammals. 
 
Gata4+/-Atoh8GFP/GFP mice exhibit structurally normal hearts and lungs 
 We next sought to understand the small increase in mortality in Gata4+/-
Atoh8GFP/GFP mice.  Gata4+/- heterozygotes have been reported to exhibit partial postnatal 
lethality when backcrossed onto a C57/BL6 background (18,19).  Although the cause of 
death was not identified in these studies, a higher incidence of cardiovascular defects 
(18,19) was identified in Gata4+/- animals compared to wild-type littermates.  In order to 
determine whether Gata4+/-Atoh8GFP/GFP mice die due to cardiac defects, we examined 
animals in late embryogenesis for these defects.  Gata4+/-Atoh8GFP/GFP mice did not 
exhibit a decrease in cardiac fractional shortening at E17.5 relative to littermates (Figure 
2.10.A), indicating that there is no myocardial or contractile defect in these animals.  
Structural abnormalities were also not detected in Gata4+/-Atoh8GFP/GFP hearts by 
histology (Figure 2.10.B-C).  These results suggest that defective heart development is 
not the cause of death in Gata4+/-Atoh8GFP/GFP mice.  To further rule out a myocardial 
cause of death in Gata4+/-Atoh8GFP/GFP mice, we generated Nkx2.5-Cre Gata4fl/+ 
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Atoh8GFP/GFP mice.  In these mice Gata4 heterozygosity is limited to the Nkx2.5-lineage 
cells, including the myocardium.  There was no loss of Nkx2.5-Cre Gata4fl/+Atoh8GFP/GFP 
mice at P1 (Table 2.7), confirming that the lethality seen in Gata4+/-Atoh8GFP/GFP mice is 
not due to more subtle cardiac defects.  
 Our zebrafish studies identified the swimbladder as a site of gata4 and atoh8 
interaction.  The mammalian lung is the closest evolutionary equivalent to the 
swimbladder; both organs share an origin from a common region of the endoderm (66) 
and express similar surfactant proteins for inflation (67).  In addition, Gata4+/- 
heterozygotes on a C57/BL6 background have also been reported to exhibit an increase in 
the pulmonary defects (18).  These results suggested that the increased lethality observed 
in Gata4+/-Atoh8GFP/GFP animals may be due to impaired lung development.  We were 
unable to detect gross structural abnormalities in Gata4+/-Atoh8GFP/GFP lungs (Figure 
2.11.A-B) or a statistically significant change in lung mass (Figure 2.11.C) at E18.5.  
There was also no change in the expression of the type II cell marker surfactant protein-C 
(Sftpc) or the type I marker Aquaporin-5 (Aqp5) by quantitative RT-PCR (Figure 2.11.D) 
at E18.5, suggesting that both type I and type II cells are present at normal numbers.  
Although we could not identify morphologic defects in lung development, we next 
examined the expression of molecular factors involved in mesenchymal-to-epithelial 
signaling in Gata4+/-Atoh8GFP/GFP animals because pulmonary expression of Atoh8 
(Figure 2.9.K-N) and Gata4 (18,37) is limited to the lung mesenchyme.  Mesenchymal 
expression of Wnt2, Fgf10, and Tbx4 has previously been shown to be required for proper 
lung development (68-70).  Expression of these factors was downregulated in both 
Gata4+/- and Atoh8GFP/GFP lungs at E12.5 (Figure 2.11.E), although we did not observe an 
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additional decrease in the expression of these factors in Gata4+/-Atoh8GFP/GFP compound 
mutants.  We also observed a decrease in the mRNA levels of the mesenchymal 
transcription factor Twist1 in Atoh8GFP/GFP lungs, and Twist1 mRNA levels were further 
decreased in Gata4+/-Atoh8GFP/GFP (Figure 2.11.E).   These results suggest that Gata4 and 
Atoh8 regulate gene expression in the developing lung mesenchyme.  However, the lack 
of any structural defects in the lung indicates that that the essential role for Atoh8 in 
zebrafish swimbladder development is not conserved in the mammalian lung. 
 
Discussion 
 Our studies revealed essential roles for Atoh8 in zebrafish cardiac and swim 
bladder development that are performed in concert with Gata and Fog transcription 
factors.  Biochemical studies indicate that ATOH8, GATA, and FOG2 can form a 
physical complex, suggesting that this molecular mechanism underlies the genetic 
interactions observed in the developing zebrafish heart.   However, our Atoh8 loss-of-
function studies in the mouse indicate that Atoh8 is not required for survival in mammals 
and that Atoh8 does not have a required role in mammalian cardiac development.  
Expression analysis of Atoh8 in mice indicate that cardiovascular expression of Atoh8 is 
primarily limited to atrial cardiomyocytes and vascular smooth muscle, possibly 
explaining the lack of a requirement for Atoh8 in the developing heart.  Our finding of 
partial postnatal lethality in Gata4+/-Atoh8GFP/GFP demonstrates that a weak genetic 
interaction between Gata4 and Atoh8 exists in mammals, but we were not able to link this 
lethality to defects in either the heart or lungs. 
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 Previous studies of ATOH8 function in vivo have identified essential roles in both 
zebrafish and mouse early embryogenesis (5,7).  While our studies identify an additional 
essential role in zebrafish development for cardiac looping, we find that neither the first 
nor second exon of Atoh8 is required for mouse development or postnatal survival.  Since 
virtually the entire coding sequence of Atoh8 is contained within these two exons, these 
findings demonstrate definitively that the ATOH8 protein is not required for mouse 
development or survival.  This result conflicts with a previous report of early embryonic 
lethality in the Atoh8Δex1-2 mouse lacking both exon 1 and 2 and intervening intron 1 (5).  
There exist several alternative explanations for the lethality seen in the Atoh8Δex1-2 mouse.  
First, it is possible that removal of intron 1 in Atoh8Δex1-2 mice may have deleted a critical 
non-coding element within this intron.  Second, it is possible that this discrepancy could 
reflect differences in strain background and the effect of modifier genes.  This is unlikely 
as both Atoh8Δex1-2 and Atoh8GFP mice were studied after being back-crossed more than 7 
generations onto a pure C57Bl/6 background.  Finally, it is possible that this difference 
reflects disruption of a genetic element outside the Atoh8 locus in the Atoh8Δex1-2 mouse.  
The Atoh8Δex1-2 mouse was created by gene targeting of ES cells using a bacterial 
artificial chromosome (BAC) targeting vector, an approach that uses much longer 
recombination arms than conventional gene targeting.  With this approach recombination 
can take place over a much larger area that, unlike gene targeting with conventional 
vectors, cannot be fully assessed by PCR or Southern blot analysis of genomic DNA 
following recombination.  Thus it seems most likely that mutations outside the coding 
region of Atoh8 are responsible for the embryonic lethality of Atoh8Δex1-2 mice. 
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 Our studies reveal a striking requirement for Atoh8 during early cardiac 
development in the zebrafish, where it functions in close association with Gata4 and Fog1 
to regulate cardiac looping (Figure 2.1 and 2.3).  Zebrafish atoh8 displays a high degree 
of sequence conservation with its murine orthologue Atoh8, particularly within the bHLH 
domain (4), suggesting the possibility of a conserved role for Atoh8 in cardiac 
development.  This possibility is strengthened by the recent identification of an ultra-
conserved cardiac enhancer in the second intron of Atoh8 present in both fish and mice 
(71), and by our finding that murine ATOH8 interacts with FOG2 and GATA4 
biochemically. In contrast to Atoh8-deficient fish, however, mice lacking ATOH8 are 
viable and do not display defects in heart development or function, even when put on a 
Gata4+/- background to further stress the putative transcriptional mechanism.  One 
explanation for this species difference appears to lie in the highly specific and restricted 
pattern of Atoh8 expression in the mouse heart.  Using two different reporter alleles, we 
detect Atoh8 predominantly within the atria during development and persistent expression 
that becomes primarily restricted to the right atrium in mature animals.   These results 
suggest a shift in ATOH8 function from a broad role in regulating early cardiac 
morphogenesis in the zebrafish to a more specific role in atrial development and/or 
function in mammals, and perhaps one that is more important in the mature than 
developing heart. 
 In addition to identifying an essential role for atoh8 in the development of the 
zebrafish heart and swimbladder, our studies reveal strong and specific genetic 
interaction between atoh8 and gata4 in the development of these tissues.  This genetic 
interaction is also weakly observed in mammals, as Gata4+/-Atoh8GFP/GFP mice exhibit a 
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partially lethal phenotype.  This phenotype is not due to a cardiac defect, as these animals 
have functionally and structurally normal hearts.  In addition, we were unable to 
reproduce the lethality seen in Gata4+/-Atoh8GFP/GFP mice with myocardial-specific 
deletion, further ruling out the heart as the cause of death. We could not determine the 
basis for the compound lethality observed in mice, but the neonatal timing of this 
lethality, our studies identifying the lung mesenchyme as a site of strong Atoh8 and 
Gata4 expression, and the small changes in mesenchymal-to-epithelial signaling 
observed in the developing lung of ATOH8-deficient embryos suggest that subtle defects 
in lung function around the time of birth may be causal. 
 Our biochemical studies demonstrate that mouse ATOH8, FOG2 and GATA4 are 
capable of forming a single protein complex in vitro, suggesting that ATOH8 may 
regulate GATA and FOG function in mammals as well as fish.  However, extensive 
genetic studies to define such an interaction have very little requisite interaction during 
development despite the important roles previously demonstrated for GATA4 and FOG2.   
As suggested above, part of the explanation for this species difference appears to lie in 
the restricted expression pattern of Atoh8 in the heart, the tissue in which GATA4 and 
FOG2 play required roles during development.  Another explanation for this difference 
may lie in the expression and function of GATA and FOG in the mouse versus the 
zebrafish.  Previous studies using either hypomorphic Gata4 alleles or Gata4+/- animals 
have revealed that partial loss of GATA4 is sufficient to confer a lethal phenotype 
(18,19,72).  In contrast, lethality in Fog2 heterozygotes has not been reported, suggesting 
that larger reductions in FOG2 levels may be necessary to confer phenotypes in the 
mouse.  Since our biochemical studies implicate FOG as the bridge between ATOH8 and 
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GATA, more insight into the role of ATOH8 may require a better understanding of the in 
vivo roles of FOG and its mechanism of action. 
 
Materials and Methods 
Mice 
 We used the previously reported Gata4 null allele (14), Zfpm2 (Fog2) null allele 
(31), Gata4fl floxed allele (73), CMV-Cre allele (64), Nkx2.5Cre allele (74), and Atoh8Δex1-
2 allele (5).  The Atoh8GFP, Atoh8Δex1, and Atoh8LacZΔex2 alleles were generated by creating 
gene-targeting constructs by recombineering (75).  SV/129 ES cells were targeted and 
then screened by Southern blotting.  We injected correctly targeted ES clones into 
C57/BL6 blastocysts.  Atoh8GFP/GFP mice were backcrossed onto a C57/BL6 background.  
All other mouse experiments were done in mixed genetic backgrounds.  The University 
of Pennsylvania Institutional Animal Care and Use Committee approved all animal 
protocols.  The following genotyping primers were used: 
Primers Sequence 
Atoh8GFP-WT-F 
Atoh8GFP-GFP-R 
Atoh8GFP-R 
5’- GACACAGCCAGGGAATTCC -3’ 
5’- GCAGAAGAACGGCATCAAGG -3’ 
5’- GCAGAAGAACGGCATCAAGG -3’ 
Atoh8flox-F 
Atoh8flox-R 
5’- AAGCATGGGTGTTCTCCAGATTC -3’ 
5’- GGCTGGTCATTGTCATCCAACTG -3’ 
Atoh8Δex1-F 
Atoh8Δex1-R 
5’- AAGCATGGGTGTTCTCCAGATTC -3’ 
5’- AGAGCGGAAAGGTCGTGCTCT -3’ 
Atoh8Δex2-F 
Atoh8Δex2-WT-R 
Atoh8Δex2-LacZ-R 
5’- TGGGAATAGCTGAGCAGGAT -3’ 
5’- CACACACTCGGAGAAGCTGA -3’ 
5’- ACCTGGTTGTCATGGAGGAG -3’ 
GATA4-F 
GATA4-R 
5’- CGAGACTAGTGAGACGTGCTA -3’ 
5’- ACTGGGTCTGCCATGTATCC -3’ 
Fog2-WT-F 
Fog2-Neo-F 
Fog2-R 
5’- GCCAGATCTAATTCAAACAGCGTC -3’ 
5’- GCCTGCTCTTTACTGAAGGCTCTTT -3’ 
5’- CGTACCCAAGAAAGATTCTCTGCC -3’ 
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Cre-F 
Cre-R 
5’- GAACCTGATGGACATGTTCAGGGA -3’ 
5’- CAGAGTCATCCTTAGCGCCGTAAA -3’ 
 
Zebrafish morpholino studies 
 We used Tupfel long fin (TLF) strain zebrafish for all studies except for the 
transgenic cardiac GFP studies. For the cardiac GFP studies, a previously described 
transgenic cardiac reporter zebrafish line was used (76,77).  Morpholino oligonucleotides 
were obtained from Gene Tools and injected into one-cell-stage embryos at the indicated 
doses.  For all images, embryos were mounted in 2% methylcellulose, and bright field 
and GFP images were acquired using an Olympus MVX10 microscope with an Olympus 
DP72 camera. The University of Pennsylvania Institutional Animal Care and Use 
Committee approved all animal protocols.  Morpholino sequences are listed below: 
Morpholino Sequence 
gata4 5’- TCCACAGGTGAGCGATTATTGCTCC -3’ 
zfpm1 5’- TCATGTCCCCCTTACCTCACTGGCA -3’ 
tbx5a 5’- CCTTCCTCTTCCAAAAGTACAGTCC -3’ 
mef2ca 5’- GAAAAGTGTCTTCACTGTCCGCCAT -3’ 
atoh8-MO1 5’- GTTTAGATGTGGGTTCTTCATTTCG -3’ 
atoh8-MO2 5’- CCGTGGGAATTTACCTGCTTTCTGA -3’ 
atoh8-MO3 5’- GATGTCCAGCCTGACTAATAAGTCC -3’ 
atoh8-MO1missense 5’- GTTTACATCTGCGTTGTTGATTTCG  -3’ 
Control 5’- CCTCTTACCTCAGTTACAATTTATA -3’ 
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Zebrafish in situ hybridization 
 Tupfel long fin (TLF) strain zebrafish were used for all experiments.  For the 
gata4 and atoh8 probes, the coding region of each transcript was amplified from 48 hpf 
zebrafish cDNA and cloned into pcDNA3.  Probes were synthesized using a DIG RNA 
labeling kit (Roche).  In situ hybridization was performed as previous described (78). 
 
Co-immunoprecipitation studies 
 cDNAs encoding GATA4, and FOG2 were cloned into pcDNA3.1 (Invitrogen); 
V5 epitope tags were added during cloning.  The GATA4-V217G point mutation was 
introduced by site-directed mutagenesis.  cDNA encoding ATOH8 was cloned into 
p3XFLAG-CMV-7.1 (Sigma).  Constructs were transiently transfected into HEK293T 
cells using Fugene 6 (Roche). Nuclear extracts were isolated from transfected cells as 
previously described (79).  Immunoprecipitations were performed as previously 
described (76).  Flag-tagged Atoh8 was detected with HRP-conjugated anti-Flag-M2 
antibody (1:1000, Sigma).  V5-tagged proteins were detected with monoclonal mouse 
anti-V5 antibody (1:5000, Invitrogen) and HRP-conjugated goat anti-mouse IgG antibody 
(1:5,000 Jackson ImmunoResearch Laboratories Inc.) 
 
GST fusion protein studies 
 cDNAs encoding ATOH8 and FOG2 were cloned into pGEX-4T-1 (GE 
Healthcare Life Sciences) and transformed into BL21 E. coli.  Transformed cells were 
cultured at 37C to a density of A600=0.6 and induced with 0.1mM IPTG for 4 hours at 
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30C.  Proteins were purified from cell lysates by using a Bulk GST Purification Module 
kit (GE Healthcare Life Sciences). 
 
5’ rapid amplification of cDNA ends (RACE) 
 Total RNA was isolated from postnatal day 14 (P14) Atoh8 Δex1/Δex1 heart and liver 
tissue using Trizol (Invitrogen).  5’ cDNA fragments were generated and amplified using 
the SMARTer RACE cDNA Amplification Kit (Clontech).  Following amplification, 
fragments were separated by gel electrophoresis and purified (Qiagen).  Isolated DNA 
fragments were cloned into pCR2.1-TOPO by TOPO-TA cloning (Invitrogen).  Single 
clones were isolated and sequenced to identify the cDNA fragments. 
 
Whole mount X-gal staining 
 Whole  embryos or organs were dissected at the  indicated ages.  Tissues were 
fixed and stained as previously described (80).  Images were acquired using an Olympus 
MVX10 microscope with an Olympus DP72 camera. 
 
Histology and immunostaining 
 Mouse embryos at the indicated developmental stages were dissected, fixed in 
paraformaldehyde, dehydrated, embedded in paraffin, and sectioned.  We performed 
immunostaining and hematoxylin-eosin staining.  Histological techniques were 
performed as previously described (81,82).  For immunostaining, a goat polyclonal 
antibody against GFP (1:250, Abcam) was used. Bright field and fluorescent images were 
acquired using a Nikon Eclipse 80i microscope. 
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Fetal echocardiography 
 Trans-uterine embryonic ultrasound was performed using a high-resolution Vevo 
770 micro-ultrasound system (VisualSonics Inc.) as previously reported (83). 
 
Gene expression studies 
 E12.5 lung buds and E18.5 lungs were dissected from embryonic mice.  For 
E12.5 lung buds, six lung buds were pooled together; for the E18.5 lungs, the right lung 
was used.  RNA was isolated from the tissue using Trizol (Invitrogen).  500ng of RNA 
and 50ng random hexamer primers were then used to synthesize cDNA using the 
SuperScript First-Strand Synthesis System (Invitogen).  Quantitative RT-PCR was 
performed using SYBR Green Master Mix (Applied Biosystems) on a 7900HT Fast Real-
Time PCR system (Applied Biosystems).  RT-PCR primers are listed below: 
Primer Sequence 
Surfactant Protein C-Forward 5’- ACCCTGTGTGGAGAGCTACCA -3’ 
Surfactant Protein C-Reverse 5’- TTTGCGGAGGGTCTTTCCT -3’ 
Aquaporin 5-Forward 5’- ATGAACCCAGCCCGATCTTT -3’ 
Aquaporin 5-Reverse 5’- ACGATCGGTCCTACCCAGAAG -3’ 
Wnt2-Forward 5’- TCTTGAAACAAGAATGCAAGTGTCA -3’ 
Wnt2-Reverse 5’- GAGATAGTCGCCTGTTTTCCTGAA -3’ 
FGF10-Forward 5’- TGATGCAAAGGTTATCTGCACAT -3’ 
FGF10-Reverse 5’- GAGAGTTGCACTTCATACCAAATTTC -3’ 
Tbx4-Forward 5’- TGCCCCTCAACACCTTCCCA -3’ 
Tbx4-Reverse 5’- TGGGGGTCACCTCACTGCAA -3’ 
Twist1-Forward 5’- CGGACAAGCTGAGCAAGAT -3’ 
Twist1-Reverse 5′- GGACCTGGTACAGGAAGTCG -3′ 
GAPDH-Forward 5’- ATCACCATCTTCCAGGAGCGAG -3’ 
GAPDH-Reverse 5’- GCCCTTCCACAATGCCAAAG -3’ 
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Statistics 
 P values in mouse genetic crosses were calculated using chi-squared tests.  An 
unpaired two-tailed Student’s t-test was used for all other p-values. 
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Figure 2.1.  Morpholino knockdown of atoh8 results in a failure of zebrafish heart 
looping and pericardial edema.    
 
Figure 2.1.  Morpholino knockdown of atoh8 results in a failure of zebrafish heart 
looping and pericardial edema.   (A-F) One-cell zebrafish embryos were injected with 
atoh8-MO1 morpholino (D-F) and examined at 72 hours post fertilization (hpf) in 
comparison to uninjected controls (A-C).  Transgenic fish expressing myocardial GFP 
were used in C and F.  (G-H)  One-cell zebrafish embryos were injected with atoh8-MO2 
(G) and atoh8-MO3 (H) and examined at 72 hpf. (I) Low doses of the three atoh8 
morpholinos were injected independently and in combination into one-cell embryos and 
then scored at 72 hpf for an unlooped heart tube. Graph in I shows the mean of three 
injections; errors bars represent SEM.  
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Figure 2.2.  Morpholino knockdown of atoh8 prevents swimbladder inflation. 
 
Figure 2.2.  Morpholino knockdown of atoh8 prevents swimbladder inflation.   (A-
C)  One cell zebrafish embryos were injected with atoh8-MO1.  Swimbladder inflation 
was scored at 96 hpf in injected embryos (B-C) versus wild-type (WT) embryos (A) at 96 
hpf.  Failure of swimbladder inflation was observed in morphant embryos with (B) and 
without (C) the heart phenotype.  SB=swimbladder, PE=pericardial edema.  Swimbladder 
location is outlined by dashed line. 
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Figure 2.3.  atoh8 specifically interacts with gata4 and zfpm1 in the zebrafish heart.  
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Figure 2.3.  atoh8 specifically interacts with gata4 and zfpm1 in the zebrafish heart. 
(A) Low doses of atoh8-MO1 and gata4 MO were injected alone or in combination into 
one-cell embryos and scored at 96hpf for failure of swimbladder inflation.  (B-F) Low 
doses of morpholinos were injected alone or in combination into one-cell embryos.  
Embryos were scored at 72 hpf for the unlooped heart tube phenotype.   The following 
combinations were used: atoh8-MO1 + gata4 (B), atoh8-MO1 + mef2ca (C), atoh8-MO1 
+ tbx5-a (D), atoh8-MO1 + zfpm1 (E), and gata4 + zfpm1 (F).  (G) Doses for atoh8-
MO1, zfpm1, and gata4 morpholinos were lowered as indicated and injected individually 
or in combination into one-cell embryos.  Embryos were scored at 72 hpf for the 
unlooped heart tube phenotype.  For all experiments, control morpholino was used to 
equalize amount of the total morpholino used in each injection.  Graphs show the mean of 
3 injections with >50 embryos per injection; errors bars represent SEM.  * P<0.05, ** 
P<0.01, *** P<0.001 
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Figure 2.4.  ATOH8 physically interacts with FOG2 and indirectly with GATA4 via 
FOG2.   
 
Figure 2.4.  ATOH8 physically interacts with FOG2 and indirectly with GATA4 via 
FOG2.  (A-B) FLAG-ATOH8, V5-GATA4-WT, V5-GATA4-V217G, and V5-FOG2 
were transiently expressed in HEK293T cells in the indicated combinations, 
immunoprecipitated with anti-FLAG antibody, and detected by Western blotting with 
anti-Flag or anti-V5 antibodies as indicated.  V5-GATA4-WT is wild-type GATA4 with 
a V5 epitope tag.  V5-GATA4-V217G is a GATA4 mutant with a V5 epitope tag and a 
valine-to-glycine point mutation at residue 217 that abolishes FOG2-GATA4 interaction. 
  
 42 
Figure 2.5.   atoh8 expression in the zebrafish. 
 
Figure 2.5.   atoh8 expression in the zebrafish.  (A-B) atoh8 expression by in situ 
hybridization at 13 hours post fertilization (hpf).  Lateral (A) and dorsal (B) views are 
shown.  (C-E) In situ hybridization for atoh8 (C-D) and gata4 (E) at 30 hpf.  Lateral (C) 
and dorsal (D) views are shown for atoh8.  Arrowheads in C and E indicate heart tubes.  
(F) Expression of atoh8 at 48 hpf by in situ hybridization.  Arrowhead in F indicates 
heart. 
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Figure 2.6.   Targeting strategy for the Atoh8GFP allele.   
 
Figure 2.6.   Targeting strategy for the Atoh8GFP allele.  The eGFP coding sequence 
followed by a stop codon was inserted into exon 1.  The PGK-Neo cassette was removed 
in vivo by crossing these mice to a FLP-expressing mouse line to promote excision 
between the FRT sites (blue circles).  (B) Southern blot with NdeI digest to detect correct 
targeting in embryonic stem cells is shown. 
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Figure 2.7.  Targeting strategy for the Atoh8fl and Atoh8Δex1 alleles.  
 
Figure 2.7.  Targeting strategy for the Atoh8fl and Atoh8Δex1 alleles.  (A) LoxP sites 
were inserted to flank exon 1 of the Atoh8 gene.  The 5’ loxP was inserted upstream of a 
conserved genomic region extending 517 bp 5’ of the transcriptional start site.  Atoh8Δex1 
allele was generated by Cre-mediated recombination of the Atoh8fl allele in the mouse 
germline using CMV-Cre mouse line.  Green triangles are LoxP sites; blue circles are 
FRT sites.  (B) Southern blot with SpeI digest to detect correct targeting in embryonic 
stem cells.  (C) Reverse-transcriptase PCR using primers in Atoh8 exons 1 and 3 to 
confirm loss of exon 1 transcripts in Atoh8Δex1/Δex1 in the hearts of postnatal day 21 mice. 
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Table 2.1. Survival of Atoh8∆ex1/∆ex1 mice at postnatal day 14. 
 
 
 
  
Cross: Atoh8∆ex1/+ X Atoh8∆ex1/+ 
Genotype Number Observed % Mendelian % 
Atoh8+/+ 43 30% 25% 
Atoh8∆ex1/+ 70 48% 50% 
Atoh8∆ex1/∆ex1 32 22% 25% 
Total 145  P=0.39 
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Table 2.2. Survival of Atoh8GFP/GFP mice at postnatal day 14. 
 
 
  
Cross: Atoh8GFP/+ X Atoh8GFP/+ 
Genotype Number Observed % Mendelian % 
Atoh8+/+ 28 34% 25% 
Atoh8GFP/+ 34 40% 50% 
Atoh8GFP/GFP 22 26% 25% 
Total 84  P=0.14 
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Figure 2.8.  Targeting strategy for the Atoh8 LacZΔex2 allele.  
 
Figure 2.8.  Targeting strategy for the Atoh8 LacZΔex2 allele.  (A) An IRES-LacZ gene 
trap cassette was inserted in place of Atoh8 exon 2 to generate the Atoh8 LacZΔex2 allele.  
The first three nucleotides of exon 2 were left in place to preserve the endogenous splice 
acceptor site. Green triangles are LoxP sites; blue circles are FRT sites.  (B) Southern 
blot with NcoI digest was used to detect correct targeting in embryonic stem cells.  (C) 
Reverse-transcriptase PCR using primers in Atoh8 exons 1 and 3 to confirm loss of 
transcripts in Atoh8LacZ∆ex2/LacZ∆ex2 in the hearts of postnatal day 21 mice.  
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Table 2.3. Survival of Atoh8LacZ∆ex2/LacZ∆ex2/+ mutant mice at postnatal day 14. 
 
 
  
Cross: Atoh8LacZ∆ex2/+ X Atoh8LacZ∆ex2/+ 
Genotype Number Observed % Mendelian % 
Atoh8+/+ 17 26% 25% 
Atoh8LacZ∆ex2/+ 29 45% 50% 
Atoh8LacZ∆ex2/LacZ∆ex2 19 29% 25% 
Total 65  P=0.64 
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Figure 2.9.  Atoh8 is expressed in the atria, lung mesenchyme, and vascular smooth 
muscle.   
 
 
  
 50 
Figure 2.9.  Atoh8 is expressed in the atria, lung mesenchyme, and vascular smooth 
muscle.  (A-C) Whole mount X-gal staining was performed on Atoh8LacZΔex2/+ embryos at 
E9.5 (A) and E12.5 (B-C).  C shows a magnified image of the boxed region in B with 
forelimb removed.  (D-E) Whole mount X-gal staining was performed at the indicated 
stages on isolated Atoh8LacZΔex2/+ hearts (D) and Atoh8 LacZΔex2/+ lungs (E).  (F-T) Anti-
GFP immunostaining of heart sections from Atoh8∆ex1-2/+ mice at E12.5 (F-G, K-L, O) 
and E16.5 (H-J, M-N, P-T).  Horseradish peroxidase staining was used in panels F-P and 
R-T; FITC staining was used to panel Q.  Arrowheads in Q indicate endothelial cells 
lacking GFP expression.  Scale is shown in each panel.  H=heart, Liv=liver, Ao=aorta, 
PA=pulmonary artery, RA=right atrium, RV=right ventricle, LA=left atrium, LV=left 
ventricle, IVS=interventricular septum, ProxAir=proximal airway, DA= distal airway, 
PV=pulmonary vein, Art=artery. 
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Table 2.4. Survival of Zfpm2+/- Atoh8GFP/GFP mice at postnatal day 1 (P1) and 
postnatal day 14 (P14). 
 
Cross: Atoh8∆GFP/+ X Zfpm2+/- Atoh8GFP/+ Age: P1 
Genotype Number Observed % Mendelian % 
Atoh8+/+ 3 7% 12.5% 
Atoh8GFP/+ 16 40% 25% 
Atoh8GFP/GFP 5 12% 12.5% 
Zfpm2+/- Atoh8+/+ 2 5% 12.5% 
Zfpm2+/- Atoh8GFP/+ 11 27% 25% 
Zfpm2+/- Atoh8GFP/GFP 4 10% 12.5% 
Total 41  P=0.27 
    
Cross: Atoh8∆GFP/+ X Zfpm2+/- Atoh8GFP/+ Age: P14 
Genotype Number Observed % Mendelian % 
Atoh8+/+ 3 9% 12.5% 
Atoh8GFP/+ 11 34% 25% 
Atoh8GFP/GFP 3 9% 12.5% 
Zfpm2+/- Atoh8+/+ 2 6% 12.5% 
Zfpm2+/- Atoh8GFP/+ 9 28% 25% 
Zfpm2+/- Atoh8GFP/GFP 4 12% 12.5% 
Total 32  P=0.73 
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Table 2.5.  Survival of Gata4+/- Atoh8GFP/GFP mice at postnatal day 1 (P1) and 
postnatal day 14 (P14). 
 
Cross: Atoh8∆GFP/+ X Gata4+/- Atoh8GFP/+ Age: P1 
Genotype Number Observed % Mendelian % 
Atoh8+/+ 40 18% 12.5% 
Atoh8GFP/+ 66 30% 25% 
Atoh8GFP/GFP 25 11% 12.5% 
Gata4+/- Atoh8+/+ 24 11% 12.5% 
Gata4+/- Atoh8GFP/+ 49 22% 25% 
Gata4+/- Atoh8GFP/GFP 15 7% 12.5% 
Total 219  P=0.0106 
    
Cross: Atoh8∆GFP/+ X Gata4+/- Atoh8GFP/+ Age: P14 
Genotype Number Observed % Mendelian % 
Atoh8+/+ 43 22% 12.5% 
Atoh8GFP/+ 69 35% 25% 
Atoh8GFP/GFP 23 12% 12.5% 
Gata4+/- Atoh8+/+ 21 11% 12.5% 
Gata4+/- Atoh8GFP/+ 35 18% 25% 
Gata4+/- Atoh8GFP/GFP 8 4% 12.5% 
Total 199  P<0.0001 
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Table 2.6.  Viability of Gata4+/- Atoh8GFP/GFP embryos at embryonic day 17.5. 
 
Cross: Atoh8∆GFP/+ X Gata4+/- Atoh8GFP/+ Age: E17.5 
Genotype Number Observed % Mendelian % 
Atoh8+/+ 4 10% 12.5% 
Atoh8GFP/+ 11 27% 25% 
Atoh8GFP/GFP 2 5% 12.5% 
Gata4+/- Atoh8+/+ 8 19% 12.5% 
Gata4+/- Atoh8GFP/+ 11 27% 25% 
Gata4+/- Atoh8GFP/GFP 5 12% 12.5% 
Total 41  P=0.56 
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Figure 2.10. Gata4+/-Atoh8GFP/GFP embryonic hearts are functionally and structurally 
normal.  
 
Figure 2.10. Gata4+/-Atoh8GFP/GFP embryonic hearts are functionally and structurally 
normal. (A) Ejection fraction was determined for Gata4+/-Atoh8GFP/GFP and littermates at 
E17.5.  N for each genotype is shown in panel.  Graph shows mean of all samples of that 
genotype; errors bars represent SEM.  (B-C)  Hematoxylin-eosin staining was performed 
on E17.5 heart sections from control (B) and Gata4+/-Atoh8GFP/GFP (C) embryos.  Scale is 
shown in each panel. 
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Table 2.7.  Survival of Nkx2.5-Cre Gata4fl/+ Atoh8GFP/GFP embryos at postnatal day 1. 
 
Cross: Nkx2.5-Cre Atoh8∆GFP/+ X Gata4fl/fl Atoh8GFP/GFP Age: P1 
Genotype Number Observed % Mendelian % 
Gata4fl/+ Atoh8GFP/+ 7 25% 25% 
Gata4fl/+ Atoh8GFP/GFP 9 32% 25% 
Nkx2.5-Cre Gata4fl/+ Atoh8GFP/+ 2 7% 25% 
Nkx2.5-Cre Gata4fl/+ Atoh8GFP/GFP 10 36% 25% 
Total 28  P=0.14 
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Figure 2.11. Gata4+/-Atoh8GFP/GFP lungs appear structurally normal but display 
defects in mesenchymal-epithelial signaling. 
 
Figure 2.11. Gata4+/-Atoh8GFP/GFP lungs appear structurally normal but display 
defects in mesenchymal-epithelial signaling.  (A-B) Hematoxylin-eosin staining was 
performed on E18.5 lung sections from control (A) and Gata4+/-Atoh8GFP/GFP (B) 
embryos. Scale is shown in each panel. (C) Lung/body weight ratios were measured at 
E18.5 to compare lung growth between indicated genotypes. N=3-6 embryos per 
genotype.  (D) Surfactant Protein C and Aquaporin 5 expression in E18.5 lungs.  N=3 
lungs/genotype.  (E) Wnt2, Fgf10, Tbx4, and Twist1 expression in E12.5 lung buds. N=6 
lung buds/genotype.  All graphs show the mean; errors bars represent SEM.  * P<0.05 
compared to WT, # P<0.05 compared to Atoh8GFP/GFP. 
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Chapter 3: Endocardial MEKK3 regulates myocardial growth  
 
Summary 
 Previous work has identified the proteins Heart-of-glass (HEG) and cerebral 
cavernous malformation 2-like (CCM2L) as endocardial factors that are required to 
generate endocardial growth factors and promote myocardial growth (58).  How HEG 
and CCM2L regulate growth factor production has remained unclear.  Here we identify 
the MAPK cascade component MEKK3 as the likely link between HEG-CCM2L and 
growth factor production.  We show that MEKK3 interacts with CCM2L in co-
immunoprecipitation experiments and that MEKK3 is required for CCM2L regulation of 
FGF transcription in cell culture.  We then establish that loss of endocardial MEKK3 
leads to a lethal loss of myocardial growth, copying the phenotype seen Heg-/- Ccm2l-/- 
mice and suggesting that MEKK3 is involved in the same pathway as HEG and CCM2L.  
We then demonstrate genetic interaction between Heg and Map3k3 (encoding MEKK3), 
further connecting MEKK3 to the HEG-CCM pathway in vivo. 
 
Introduction 
 Cerebral cavernous malformations (CCM) are vascular lesions that develop 
within the central nervous system that can lead to hemorrhagic stroke (48).  CCM lesions 
are linked to mutations in CCM1, CCM2, or CCM3 (49-51); biochemical studies have 
demonstrated that these proteins form a complex where CCM1 binds CCM2, which then 
binds CCM3 (52).  Genetic studies of these genes in mouse models have reveal a 
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requirement for these genes in early vascular development in addition to their role in 
CCM pathogenesis. 
 In our lab’s previous work on CCM, we identified two additional components of 
the CCM complex: Heart-of-glass (HEG) and cerebral cavernous malformation 2-like 
(CCM2L).  Neither of HEG nor CCM2L is involved in traditional CCM lesion formation.  
Heg is a transmembrane protein that can interact with the CCM complex by binding 
CCM1 (52).  Loss of the zebrafish homologue Heg has been reported to result in 
defective myocardial growth (56); in the mouse, loss of Heg results in death in half of the 
animals by weaning from either pulmonary hemorrhage or from myocardial ruptures 
secondary to local patches of thin myocardium (52).  CCM2L is a paralogue of CCM2 
can interact with CCM1 but cannot bind with CCM3 (58).  Ccm2l-/- mice are viable; 
however, Heg-/- Ccm2l-/- double mutant mice are lethal by E10.5 from heart failure 
secondary to reduced myocardial proliferation (58). Heg-/- Ccm2l-/- embryos had normal 
appearing endocardium but were found to have reduced levels of FGF16, an endocardial-
to-myocardial growth factor that has previously been linked to myocardial proliferation 
(45,59). 
 Although our lab identified a requirement for HEG and CCM2L in regulating 
endocardial FGF16 transcription, the mechanism for this regulation remains unclear.  
HEG is embedded with the cell membrane and CCM2L is presumably in a complex with 
CCM1 and HEG at the membrane, leading us to conclude that HEG and CCM2L must 
facilitate some type of signaling pathway that regulates growth factor transcription.  We 
identified a likely candidate in MEKK3, a MAPK kinase kinase kinase.  MEKK3 has 
previously been shown to physically interact with CCM2 (84), suggesting it could also be 
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a binding partner of CCM2L.  Mice lacking MEKK3 are dead by E10.5 with widespread 
vascular defects (85).  These mice also exhibited myocardial thinning, although these 
defects could be secondary to the vascular defects, precluding a clear understanding of 
the role of MEKK3 in the heart. 
We hypothesized that HEG-CCM2L control endocardial growth factor production 
by regulating MEKK3.  To test this hypothesis, we investigated whether MEKK3 could 
physically interact with CCM2L and regulate CCM2L activation of FGF16 transcription.  
We then investigated whether endocardial MEKK3 was required for myocardial growth 
in the developing heart. 
 
Results 
MEKK3 can physically interact with either CCM2 or CCM2L 
  In order to identify signaling pathways that could connect the HEG-CCM 
complex with transcription of FGF growth factors, we looked at known interacting 
partners with CCM proteins.  MEKK3 (encoded by the gene Map3k3) is a MAPK kinase 
kinase kinase that has previously been reported to be required for vascular development 
(85) and that has been reported to physically interact with CCM2 (84).  Because of the 
high homology between CCM2 and CCM2L, we hypothesized that MEKK3 could 
physically interact with CCM2L.  In order to test this hypothesis, we performed co-
immunoprecipitation experiments to detect physical interaction between MEKK3 and 
either CCM2 or CCM2L.  We overexpressed HA-tagged MEKK3 (HA-MEKK3) with 
either FLAG-tagged CCM2 (FLAG-CCM2) or FLAG-tagged CCM2L (FLAG-CCM2L) 
in HEK293T cells and then performed immunoprecipitations with anti-FLAG antibodies.  
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HA-MEKK3 co-immunoprecipitated with either FLAG-CCM2 or FLAG-CCM2L 
(Figure 3.1), indicating that MEKK3 can physically interact with CCM2L in addition to 
CCM2.  These results are compatible with a mechanism where MEKK3 physically 
interacts with CCM2L and facilitates signaling from the HEG-CCM1-CCM2L complex. 
 
CCM2L increases FGF16 transcription via a MEKK3-dependent mechanism 
 Having demonstrated that MEKK3 could physically interact with CCM2L, we 
next asked whether MEKK3 was required for CCM2L regulation of FGF transcription.   
Our lab previously developed a cell culture model where adenoviral-mediated 
overexpression of CCM2L in human microvascular endovascular cells (HMVEC) leads 
to an upregulation of FGF16 transcription (58).  In order to determine whether MEKK3 is 
required for this regulation of FGF16 expression, we infected HMVECs with CCM2L 
adenovirus or control LacZ adenovirus in the presence of MEKK3 siRNA or scramble 
control siRNA.  Adenoviral overexpression of CCM2L results in an approximately three-
fold increase in FGF16 expression (Figure 3.2).  siRNA-mediated knockdown of 
MEKK3 in HMVECs blocks this increase in FGF16 (Figure 3.2).  This result indicates 
that CCM2L regulates FGF16 via a MEKK3-dependent mechanism and supports our 
hypothesis that MEKK3 functions in a signaling pathway between HEG-CCM2L and 
FGF transcription. 
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Nfatc1-Cre is limited to the developing endocardium and is not expressed in the 
endothelium outside the heart 
 Having shown that MEKK3 is required for CCM2L regulation of FGF16 
transcription in cell culture, we next asked whether MEKK3 is required in vivo in the 
endocardium of the developing heart.  MEKK3 is encoded by the gene Map3k3, and 
Map3k3 mutants are reported to be lethal by embryonic day 10.5-11.0 with widespread 
defects in cardiac and vascular development (85).  Although conditional Map3k3 alleles 
have been developed, the lack of a mouse Cre allele that specifically deletes in the 
endocardium while sparing the rest of the endothelium has prevented a study of the 
endocardial requirement for MEKK3.  However, a group recently has published a report 
of an endocardial-specific Cre allele, generated by insertion of an IRES-Cre cassette into 
the 3’UTR of the Nfatc1 gene (hereafter referred to as Nfatc1Cre) (46).  Within the 
endothelial lineage, this allele is reported to delete within only the endocardium and in 
the coronary vasculature endothelium that is later derived from endocardium, making this 
allele an ideal tool for determining the endocardial requirement for MEKK3. 
 In order to validate the use of the Nfatc1Cre allele as an endocardial-specific Cre 
deletor, we performed lineage analysis using the Nfatc1Cre allele and a previously 
described R26R-EYFP reporter allele (86).  Immunohistochemistry for EYFP and the 
endothelial marker PECAM was used to determine the contribution of Nfatc1 to the 
endocardium and endothelium in multiple vascular beds.  At embryonic day 10.5 (E10.5), 
Nfatc1Cre labels cells throughout the endocardium of the ventricle, atrium, and 
atrioventricular cushions (Figure 3.3.A).  EYFP reporter expression extends into the 
proximal portion of the heart outflow tract (Figure 3.3.B), but it is excluded from the 
 62 
remainder of the aortic sac and branchial arch arteries (Figure 3.3.B-C), indicating that 
Nfatc1Cre is limited to the endocardium and spares other endothelium at E10.5. 
 In order to determine the endothelial activity for Nfatc1Cre throughout 
embryogenesis, we performed additional lineage tracing experiments on Nfatc1Cre R26R-
EYFP neonates on postnatal day 1 (P1).  EYFP reporter expression overlapped with 
PECAM expression at P1 throughout the endocardium (Figure 3.3.D-G).  EYFP reporter 
expression was also seen in PECAM+ capillary and coronary artery endothelium in the 
heart (Figure 3.3.D-G), a finding consistent with a previous report that endocardial cells 
contribute to a significant portion of the cardiac vasculature (46).  Nfatc1Cre lineage cells 
also contributed to other endocardium-derived structures, including the cardiac valves 
(Figure 3.3.H) and the endothelium of the proximal aorta (Figure 3.3.I).   We next 
examined non-cardiac endothelium in P1 embryos to determine whether the Nfatc1Cre 
allele was active in these cells.  In contrast to the widespread expression of the EYFP 
reporter in endocardial lineages, there is no EYFP expression in the endothelium of the 
liver (Figure 3.3.J-K) or kidney (Figure 3.3.L-M) at P1, indicating that the Nfatc1Cre 
allele is not active in endothelial cells other than the endocardium and the cardiac 
vasculature.  These results demonstrate that the expression of Nfatc1Cre allele is limited to 
the endocardium and that this Cre allele can be used to create an endocardial-specific 
deletion of MEKK3. 
 
Endocardial MEKK3 is required for mouse survival and myocardial development 
 In order to determine whether MEKK3 is required in the endocardium, we 
combined the Nfatc1Cre conditional allele with a previously reported Map3k3 (encoding 
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MEKK3) floxed allele in which loxP sites flank exons 12-13, which encode several 
subdomains of the MEKK3 kinase domain (87).  Deletion of these exons has been shown 
to result in a kinase-dead form of MEKK3 (87), and thus cells homozygous for this 
mutation will be null for functional MEKK3.  We were unable to find any Nfatc1Cre 
Map3k3fl/- neonates when litters were genotyped at birth (Table 3.1), indicating that loss 
of endocardial MEKK3 results in death during embryogenesis.  Timed matings were then 
performed to determine when Nfatc1Cre Map3k3fl/- embryos died.  No viable Nfatc1Cre 
Map3k3fl/- animals were found at E14.5 (Table 3.2), indicating that endocardial loss of 
MEKK3 is lethal before this time point.  At E10.5, Nfatc1Cre Map3k3fl/- embryos were 
found at approximately 80% of the expected rate (Table 3.2), indicating that most 
Nfatc1Cre Map3k3fl/- embryos are viable at this embryonic stage.  By E11.5, the number of 
Nfatc1Cre Map3k3fl/- embryos had decreased to less than 40% of the Mendelian prediction 
(Table 3.2).  Although additional crosses are need to determine the viability of these 
embryos at E12.5 and E13.5, these results suggest that endocardial deletion of MEKK3 
leads to embryonic loss beginning at E10.5-E11.5, with loss of all embryos by E14.5. 
 In order to determine the cause of death in Nfatc1Cre Map3k3fl/- embryos, we used 
hematoxylin & eosin (H&E) staining to examine the structure of viable Nfatc1Cre 
Map3k3fl/- embryos at E10.5 and E11.5.  Nfatc1Cre Map3k3fl/- embryos had profound 
myocardial thinning relative to littermate controls at E10.5 (Figure 3.4.A-D) and E11.5 
(Figure 3.4.E-H), indicating that endocardial loss of MEKK3 has a deleterious effect on 
myocardial development.  In contrast, the endocardium was indistinguishable between 
Nfatc1Cre Map3k3fl/- embryos and littermate controls (Figure 3.4.A-D, see arrowheads), 
suggesting that endocardial development proceeds normally in these embryos.  These 
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results indicate that endocardial loss of MEKK3 results in lethal defects in myocardial 
development.  This result is nearly identical to the phenotype our lab previously observed 
in Heg-/- Ccm2l-/- mouse (58).  This is consistent with our hypothesis that MEKK3 
functions downstream of HEG and CCM2L to promote endocardial production of growth 
factors to facilitate myocardial growth, although further analysis of Nfatc1Cre Map3k3fl/- 
embryos is needed to determine whether these animals have the same defects in 
proliferation and endocardial FGF production as were seen in Heg-/- Ccm2l-/- embryos. 
 
Endocardial CCM1 is required for survival in the embryonic mouse 
 Although the endothelial functions of CCM1, CCM2, and CCM3 in development 
have been studied in mice with endothelial-specific (Tie2Cre) deletions of these genes, the 
function of these proteins in the endocardium has remained unclear due to very early 
embryonic death that occurs secondary to vascular defects (53-55).  It would be 
particularly interesting to examine embryos lacking endocardial CCM1 for defects 
similar to Heg-/- Ccm2l-/- and Nfatc1Cre Map3k3fl/- embryos, due to the fact that we 
suspect CCM1 forms a complex with HEG and CCM2L.  Our Nfatc1Cre lineage trace and 
our positive results with Nfatc1Cre Map3k3fl/- embryos suggest that the Nfatc1Cre allele 
could be used to determine the endocardial requirement for CCM proteins.  In order to 
determine the function of CCM1 in the endocardium, we combined the Nfatc1Cre allele 
with the Krit1fl allele (Krit1 encodes CCM1).  Nfatc1Cre Krit1fl/fl mice are not found at 
birth (Table 3.3), indicating that endocardial CCM1 is required for survival.  We are now 
undertaking timed matings to characterize the embryonic defects present in these mice 
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and to determine whether endocardial CCM1 has a similar role in myocardial growth as 
HEG, CCM2L, and MEKK3. 
 
Heg and Map3k3 genetically interact in the endothelium and endocardium 
 In our previous studies of HEG and CCM proteins, our lab has utilized compound 
genetic mutants to demonstrate genetic interaction between different members of this 
complex.  For example, in our studies of the Heg mutant mouse, our lab showed that Heg-
/- CCM2+/- mice phenocopy the embryonic vascular defects of CCM2-/- mice (52), 
implicating Heg in this developmental process.  Such interactions provide evidence for 
shared function in vivo.  Because endocardial-specific deletion of MEKK3 displays a 
similar phenotype to the Heg-/- Ccm2l-/- mouse, we hypothesized that Map3k3 (encoding 
MEKK3) would exhibit genetic interaction with Ccm2l and Heg.  To test this hypothesis, 
we generated Ccm2l-/- Map3k3+/- and Heg-/- Map3k3+/-.  Ccm2l-/- Map3k3+/- mice were 
viable and had no overt phenotypes (data not shown).  Viable Heg-/- Map3k3+/- mice, 
however, were not found at birth (Table 3.4).  Timed matings revealed that Heg-/- 
Map3k3+/- die between E12.5 and E14.5 (Table 3.4).  At E12.5 Heg-/- Map3k3+/- embryos 
exhibited profound myocardial thinning relative to littermate controls (Figure 3.5), 
although this phenotype was not completely penetrant.  Viable Heg-/- Map3k3+/- animals 
at E13.5 did not have a decrease in heart function at this time point (Figure 3.6).  Given 
that our genetic crosses indicate that all animals are dead by E14.5, this result suggests 
that cardiac function is preserved in these animals until E13.5 and rapidly deteriorates by 
E14.5. 
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 The embryonic lethality and myocardial thinning that we observe in Heg-/- 
Map3k3+/- animals demonstrate that a genetic interaction exists between Heg and 
Map3k3.  We hypothesized that this interaction was taking place within the endothelium 
and possibly specifically within the endocardium.  In order to determine what cell type 
underlies this interaction, we used Tie2Cre and Nfatc1Cre conditional alleles to respectively 
generate Tie2Cre Heg-/- Map3k3fl/+and Nfatc1Cre Heg-/- Map3k3fl/+ mice.  In these mice, 
Heg deletion is global while Map3k3 heterozygosity is limited to all endothelium (with 
Tie2Cre) or to only endocardium (with Nfatc1Cre).  If the Heg-/- Map3k3+/- interaction we 
observe is dependent on endocardial function of Map3k3, we would predict Nfatc1Cre 
Heg-/- Map3k3fl/+ mice would copy the phenotype of Heg-/- Map3k3+/- mice; if it is 
dependent on pan-endothelial function of Map3k3, we would predict Tie2Cre Heg-/- 
Map3k3fl/+ mice would copy the phenotype of Heg-/- Map3k3+/- mice.  In our matings 
Tie2Cre Heg-/- Map3k3fl/+ mice were lethal at P1 and almost completely lethal at E14.5 
(Table 3.5), mimicking the lethality we observe in Heg-/- Map3k3+/- mice.  In contrast, 
approximately half of the Nfatc1Cre Heg-/- Map3k3fl/+ mice were viable at E14.5 and at P1 
(Table 3.6).  These results suggest that the lethality we observed from genetic interaction 
between Heg and Map3k3 is partially due to endocardial defects (as shown by the 50% 
lethality in Nfatc1Cre Heg-/- Map3k3fl/+ mice) and partially due to other endothelial defects 
(as shown by the increased lethality seen in Tie2Cre Heg-/- Map3k3fl/+ mice).  We are 
performing histology on these conditional mice to determine whether they have similar 
cardiac pathology to Heg-/- Map3k3+/- mice. 
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Discussion 
 Our studies of MEKK3 support our hypothesis that MEKK3 operates downstream 
of HEG and CCM2L to facilitate growth factor production in the endocardium to support 
myocardial growth.  We demonstrate that MEKK3 can physically interact with CCM2L 
and that MEKK3 is required in endothelial cell culture models for CCM2L-stimulated 
FGF16 production.  Our Nfatc1Cre Map3k3fl/- mouse studies demonstrate that endocardial 
MEKK3 is required for myocardial growth, a finding consistent with a role for MEKK3 
as an activator of endocardial growth factor production.  Finally, we identify genetic 
interaction between Heg and Map3k3, providing in vivo evidence connecting MEKK3 to 
the HEG-CCM complex. 
 While previous studies of Map3k3-/- embryos had reported myocardial thinning 
defects with loss of MEKK3 (85), it was unclear if this defect was due to a loss of 
endocardial or myocardial MEKK3, or if it was a secondary consequence of global 
vasculature defects.  Our studies with the Nfatc1Cre Map3k3fl/- mice clearly identify an 
endocardial requirement for MEKK3 in facilitating myocardial growth.  Our lineage trace 
experiments with the Nfatc1Cre R26R-EYFP mice demonstrate that Nfatc1Cre activity is 
limited to the endocardium and indicate that the phenotypes in Nfatc1Cre Map3k3fl/- mice 
are due to endocardial loss of MEKK3.  In addition, the normal appearance of the 
endocardium in Nfatc1Cre Map3k3fl/- suggests that the phenotype is due to a specific loss 
of endocardial growth factors rather than a loss of endocardial cells.  This phenotype—
loss of myocardium with normal endocardium—is a close copy of the Heg-/- Ccm2l-/- 
phenotype, which supports our hypothesis that MEKK3 acts downstream of HEG and 
CCM2L to facilitate growth factor production.  Further studies are now needed to 
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confirm that Nfatc1Cre Map3k3fl/- embryos have the same type of molecular defects as 
Heg-/- Ccm2l-/- embryos.  For example, we need to determine whether reduced FGF16 
expression underlies the phenotype in Nfatc1Cre Map3k3fl/- embryos or whether changes 
in other signals are responsible. 
 In our Heg-/- Map3k3+/- compound mutant embryos, we observed complete 
embryonic lethality by E14.5, a much more severe phenotype than Heg-/- embryos, which 
largely survive into the postnatal period (52).  This lethality is a clear sign of genetic 
interaction between Heg and Map3k3, serving as possible in vivo evidence linking 
MEKK3 to the HEG-CCM complex.  It is difficult, however, to determine how whether 
Heg and Map3k3 are interacting in the endocardium or in other sites.  We observe 
myocardial thinning some Heg-/- Map3k3+/- embryos, suggesting that myocardial growth 
may be impaired in these embryos, as it is in Nfatc1Cre Map3k3fl/- or Heg-/- Ccm2l-/- 
embryos, although the phenotype is much less penetrant in Heg-/- Map3k3+/- embryos.  
However, cardiac function was preserved in viable Heg-/- Map3k3+/- embryos at E13.5, 
arguing against a cardiac cause of death in these animals.  A similar discrepancy is 
observed in Tie2Cre Heg-/- Map3k3fl/+versus Nfatc1Cre Heg-/- Map3k3fl/+ mice.  Embryonic 
death in endothelial (Tie2Cre) mutants is nearly completely penetrant, copying the 
phenotype in Heg-/- Map3k3+/- embryos, whereas endocardial (Nfatc1Cre) mutants have a 
50% reduction in death.  The most likely explanation for this outcome is two separate 
causes of death—an endocardial cause death and a separate vascular endothelial cause—
in Heg-/- Map3k3+/- embryos.  In this model, a portion of the Heg-/- Map3k3+/- population 
develops lethal myocardial thinning secondary to endocardial defects; this explains the 
thin Heg-/- Map3k3+/- hearts and the partial lethality present in Nfatc1Cre Heg-/- Map3k3fl/+ 
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embryos.  The rest of the Heg-/- Map3k3+/- population escapes this cardiac defect.  
However, these survivors likely develops a second defect within the vasculature that 
results in death at E14.5—this would explain the embryonic death we see in all Heg-/- 
Map3k3+/- embryos and nearly all Tie2Cre Heg-/- Map3k3fl/+embryos.  Further study is 
needed to examine the histology of these conditional embryos to more completely 
characterize the defects present in these animals. 
  
Materials and Methods 
Mice 
 We used the previously reported Map3k3 floxed allele (14), Heg mutant allele 
(52), Tie2Cre allele (88), Nfatc1Cre allele (46) and R26R-EYFP allele (86).  The Krit1fl is 
unpublished and was provided by our collaborator Dean Li from the University of Utah.  
All mouse experiments were done in mixed genetic backgrounds.  The University of 
Pennsylvania Institutional Animal Care and Use Committee approved all animal 
protocols.  The following genotyping primers were used: 
Primers Sequence 
Map3k3-WT-F 
Map3k3-FL-R 
Map3k3-KO-R 
5’- CATTCTTTGCCAGGCAGTGG -3’ 
5’- CTCTATAGCAGGAGAAGAGC -3’ 
5’- AGACTCACTGGTCAGAGACC -3’  
Heg-WT-F 
Heg-WT-R 
Heg-LacZ-R 
5’- CCTCCCGCGGCTCCCACAACTT -3’ 
5’- AGACTCTCACTCACCCGCGCTCA -3’ 
5’- GGCATCAGTCGGCTTGCGAGT -3’ 
Krit1-F 
Krit1-R 
5’- TGTCTCCATTCCCTCCTCCCTAC -3’ 
5’- AAACCAGCAGTCTCAACTAATCGG -3’ 
YFP-WT-F 
YFP-WT-R 
YFP-YFP-R 
5’- AAAGTCGCTCTGAGTTGTTAT -3’ 
5’- GCGAAGAGTTTGTCCTCAACC -3’ 
5’- GGAGCGGGAGAAATGGATATG -3’ 
Cre-F 
Cre-R 
5’- GAACCTGATGGACATGTTCAGGGA -3’ 
5’- CAGAGTCATCCTTAGCGCCGTAAA -3’ 
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Co-immunoprecipitation studies 
 We used the previously described HA-MEKK3 expression vector (89) and 
previously described FLAG-CCM2 and FLAG-CCM2L vectors (58) in our 
immunoprecipitation experiments.  Constructs were transiently transfected into 
HEK293T cells using Fugene 6 (Roche).  Cellular lysis and immunoprecipitations were 
performed as previously described (76).  FLAG-tagged CCM2 and CCM2L were 
detected with HRP-conjugated anti-FLAG-M2 antibody (1:1000, Sigma).  HA-tagged 
proteins were detected with monoclonal mouse anti-HA antibody (1:10000, Covance) 
and HRP-conjugated goat anti-mouse IgG antibody (1:5,000 Jackson ImmunoResearch 
Laboratories Inc.). 
 
Adenoviral Expression and siRNA studies in HMVECs 
 siRNA against human MEKK3 (Invitrogen) and scramble control siRNA 
(Invitrogen) were transfected into human microvascular endothelial cells (HMVEC) 
using RNAiMAX (Invitrogen).  24 hours after transfections, cells were infected with 
adenovirus expressing HA-CCM2L or LacZ.  Adenovirus dose was 2000gc/cell.  RNA 
was harvested from these cells 48 hours after adenoviral transfection using Trizol 
(Invitrogen).  1000ng of RNA and 50ng random hexamer primers were then used to 
synthesize cDNA using the SuperScript First-Strand Synthesis System (Invitogen).  
Quantitative RT-PCR was performed using SYBR Green Master Mix (Applied 
Biosystems) on a 7900HT Fast Real-Time PCR system (Applied Biosystems).  RT-PCR 
primers are listed below: 
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Primer Sequence 
hFGF16-Forward 5’- AGTGGACTCTGGCCTGTACCT -3’ 
hFGF16-Reverse 5’- TTTGTTCAGGGCCACGTAATA -3’ 
 
Histology and immunostaining 
 Mouse embryos at the indicated developmental stages were dissected, fixed in 
paraformaldehyde, dehydrated, embedded in paraffin, and sectioned.  We performed 
immunostaining and hematoxylin-eosin staining.  Histological techniques were 
performed as previously described (81,82).  For immunostaining, a goat polyclonal 
antibody against GFP (1:500, Abcam) was used to detect YFP, and a rat monoclonal 
antibody against PECAM (1:500, BD Pharmingen).  Bright field and fluorescent images 
were acquired using a Nikon Eclipse 80i microscope. 
 
Fetal echocardiography 
 Trans-uterine embryonic ultrasound was performed using a high-resolution Vevo 
770 micro-ultrasound system (VisualSonics Inc.) as previously reported (83). 
 
Statistics 
 P values in mouse genetic crosses were calculated using chi-squared tests.  An 
unpaired two-tailed Student’s t-test was used for all other p-values. 
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Figure 3.1.  MEKK3 physically interacts with CCM2 and CCM2L. 
 
Figure 3.1.  MEKK3 physically interacts with CCM2 and CCM2L.  (A) HA-
MEKK3, Flag-CCM2, and Flag-CCM2L were transiently expressed in HEK293T in the 
indicated combinations, immunoprecipitated with anti-Flag antibodies and detected by 
Western blotting with the indicated antibodies. 
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Figure 3.2.  Overexpression of CCM2L upregulates FGF16 in human microvascular 
endothelial cells via a MEKK3-dependent mechanism.  
 
Figure 3.2.  Overexpression of CCM2L upregulates FGF16 in human microvascular 
endothelial cells via a MEKK3-dependent mechanism.  (A) Adenoviral 
overexpression of CCM2L increases FGF16 mRNA levels in human microvascular 
endothelial cells (HMVEC).  siRNA-mediated knockdown of MEKK3 blocks this 
upregulation.  HMVECs were transfected with indicated siRNA (MEKK3 or scramble 
control) and infected with indicated adenoviruses 24 hours later.  Cells were harvested 24 
hours after adenoviral infection.  Graph shows mean of 4 replicates +/- sem.  *** P < 
0.001. 
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Figure 3.3.  Nfatc1Cre deletes specifically in the endocardium and coronary 
endothelium. 
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Figure 3.3.  Nfatc1Cre deletes specifically in the endocardium and coronary 
endothelium.  (A-C) Nfatc1Cre lineage tracing with the R26R-YFP reporter labels the 
E10.5 endocardium while sparing the aorta and brachial arch arteries.  (D-I) Nfatc1Cre 
lineage cells contribute to the endocardium, cardiac valves, and the coronary endothelium 
at P1.  R26R-YFP reporter expression overlaps with PECAM expression in the 
endocardium and coronary endothelium (D-G).  YFP expression is also seen in 
endocardium-derived structures such as the cardiac valves (H) and the proximal aortic 
endothelium (I).  (J-M)  Nfatc1Cre lineage cells do not contribute to PECAM+ endothelial 
cells in the liver (J-K) or kidney (L-M) vascular beds.  K and M show higher 
magnification images of J and L, respectively.  Abbreviations: Atr=atrium, 
AVC=atrioventricular cushion, Vent=common ventricle, Ao=aortic sac, BAA=branchial 
arch artery, LV=left ventricle, RV=right ventricle, CA=coronary artery. 
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Table 3.1.  Survival of Nfatc1Cre/+ Map3k3fl/- mice at P1. 
 
 
 
 
  
Cross:  Nfatc1Cre/+ Map3k3+/- X Map3k3fl/fl 
Genotype Number Observed % Mendelian % 
Map3k3fl/+ 14 25% 25% 
Map3k3fl/- 19 33% 25% 
Nfatc1Cre/+ Map3k3fl/+ 21 42% 25% 
Nfatc1Cre/+ Map3k3fl/- 0 0% 25% 
Total 54  P<0.001 
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Table 3.2.  Embryonic survival of Nfatc1Cre/+ Map3k3fl/- mice. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Cross:  Nfatc1Cre/+ Map3k3+/- X Map3k3fl/fl 
Age: E10.5 
Genotype Number Observed % Mendelian % 
Map3k3fl/+ 29 29% 25% 
Map3k3fl/- 29 29% 25% 
Nfatc1Cre/+ Map3k3fl/+ 23 23% 25% 
Nfatc1Cre/+ Map3k3fl/- 19 19% 25% 
Total 100  P=0.410 
 
Age: E11.5 
Genotype Number Observed % Mendelian % 
Map3k3fl/+ 15 27% 25% 
Map3k3fl/- 23 42% 25% 
Nfatc1Cre/+ Map3k3fl/+ 12 22% 25% 
Nfatc1Cre/+ Map3k3fl/- 5 9% 25% 
Total 55  P=0.007 
 
Age: E14.5 
Genotype Number Observed % Mendelian % 
Map3k3fl/+ 16 31% 25% 
Map3k3fl/- 11 22% 25% 
Nfatc1Cre/+ Map3k3fl/+ 24 47% 25% 
Nfatc1Cre/+ Map3k3fl/- 0 0% 25% 
Total 51  P<0.001 
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Figure 3.4. Nfatc1Cre Map3k3fl/- embryos exhibit myocardial thinning. 
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Figure 3.4. Nfatc1Cre Map3k3fl/- embryos exhibit myocardial thinning.  (A-D) 
Nfatc1Cre Map3k3fl/- embryos exhibit myocardial thinning relative to littermates at E10.5.  
The endocardium (arrowheads in A-D) is intact and indistinguishable between Nfatc1Cre 
Map3k3fl/- embryos and controls.  B and D are higher magnification images of boxed 
region in A and C, respectively.  (E-H) Nfatc1Cre Map3k3fl/- embryos exhibit myocardial 
thinning relative to littermates at E11.5.  F and H are higher magnification images of 
boxed region in E and G, respectively.  Scale bars are 100µm in A, C, E, G, and 50µm in 
B, D, F, H. 
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Table 3.3.  Survival of Nfatc1Cre/+ Krit1fl/fl mice at P1. 
 
 
 
 
 
  
Cross:  Nfatc1Cre/+ Krit1fl/+ X  Krit1fl/fl 
Genotype Number Observed % Mendelian % 
Krit1fl/+ 13 48% 25% 
Krit1fl/fl 6 22% 25% 
Nfatc1Cre/+ Krit1fl/+ 8 30% 25% 
Nfatc1Cre/+ Krit1fl/fl 0 0% 25% 
Total 27  P=0.005 
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Table 3.4.  Survival of Heg-/- Map3k3+/- mice. 
 Cross: Heg-/- X Heg+/- Map3k3+/- 
Age Heg+/- Heg-/- Heg
+/- 
Map3k3+/- 
Heg-/- 
Map3k3+/- Total P-value 
E12.5 14 11 10 7 42 0.50 
E13.5 20 16 15 7 58 0.10 
E14.5 19 17 13 0 49 <0.001 
P1 27 15 32 0 74 <0.001 
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Figure 3.5.  Heg-/- Map3k3+/- hearts exhibit myocardial thinning at E12.5. 
 
Figure 3.5.  Heg-/- Map3k3+/- hearts exhibit myocardial thinning at E12.5.  (A-D) 
Heg-/- Map3k3+/- hearts (C-D) exhibit myocardial thinning relative to littermate controls 
(A-B).  B and D show higher magnification image of ventricular wall from A and C, 
respectively.  Scale bars are 100µm in A, C, and 50µm in B, D. 
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Figure 3.6. Cardiac function is normal in E13.5 Heg-/- Map3k3+/- embryos. 
 
Figure 3.6.  Cardiac function is normal in E13.5 Heg-/- Map3k3+/- embryos.  
Fractional shortening was measured on E13.5 embryos by echocardiography.  Dots show 
fractional shortening for individual embryo; graph lines show mean +/- sem for each 
genotype.  No significant changes were observed between the genotypes. 
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Table 3.5.  Survival of Tie2Cre Heg-/- Map3k3fl/+ mice. 
 Cross: Heg-/- X Heg+/- Map3k3+/- 
Age Heg
+/- 
Map3k3fl/+ 
Heg+/- 
Map3k3fl/+ 
Tie2Cre 
Heg+/- 
Map3k3fl/+ 
Tie2Cre 
Heg-/- 
Map3k3fl/+ 
Total P-value 
E14.5 15 20 18 2 55 0.003 
P1 17 14 21 0 52 <0.001 
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Table 3.6.  Survival of Nfatc1Cre Heg-/- Map3k3fl/+ mice. 
 Cross: Heg-/- X Heg+/- Map3k3+/- 
Age Heg
+/- 
Map3k3fl/+ 
Heg+/- 
Map3k3fl/+ 
Nfatc1Cre 
Heg+/- 
Map3k3fl/+ 
Nfatc1Cre 
Heg-/- 
Map3k3fl/+ 
Total P-value 
E14.5 9 7 10 4 30 0.423 
P1 12 14 20 6 52 0.052 
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Chapter 4: Conclusions and Future Directions 
 
Summary 
 ATOH8 is a highly conserved bHLH transcription factor in vertebrates whose in 
vivo role is largely undefined.  In Chapter 2, I utilized a combination of zebrafish and 
mouse models to characterize the requirements and functions of ATOH8.  Through 
morpholino studies in the zebrafish, I identified a requirement for atoh8 in the developing 
zebrafish in regulating heart looping and swimbladder inflation.  I further demonstrated 
that atoh8 specifically interacts with gata4 and zfpm1 (encoding Fog1) in zebrafish heart 
development.  These results, combined with co-immunoprecipitation experiments 
showing that murine ATOH8 physically interacts with murine FOG2, suggest that Atoh8 
functions as a co-factor with the Gata4-Fog1 complex in zebrafish.  However, multiple 
Atoh8 mutant mouse models failed to exhibit any overt phenotype, in contrast to the 
zebrafish.  Partial postnatal lethality was observed in Gata4 and Atoh8 compound 
mutants, suggesting that a weak genetic interaction may exist in the mouse, but to a 
much-reduced extent relative to the zebrafish. 
 Prior work in the Kahn lab had identified the transmembrane protein HEG and the 
adaptor protein CCM2L as required endocardial factors for proper generation of FGF 
growth signals for the myocardium.  How HEG and CCM2L regulate growth factor 
production, however, had remained unclear.  In Chapter 3, I identify MEKK3 as a likely 
intermediary between HEG-CCM2L and growth factor production.  I show that MEKK3 
is capable of physically interacting with CCM2L and is required for CCM2L regulation 
of FGF production in vitro.  I further show that endocardial MEKK3 is required for 
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myocardial proliferation, linking MEKK3 to endocardial growth factor signaling.  I also 
identify genetic interaction between Heg and Map3k3 (encoding MEKK3) in compound 
mutant mice, further linking MEKK3 to the HEG-CCM complex in vivo.  It remains to be 
determined which growth signals are specifically disrupted in MEKK3 endocardial 
mutants, what signals activate MEKK3 in the endocardium, and what pathways are 
activated downstream of MEKK3 within the endocardium. 
 
Future Directions: Atoh8 
 My studies on Atoh8 in murine development have definitively shown that Atoh8 is 
not required for survival in developing mammals.  Furthermore, although we do see weak 
genetic interaction between the Atoh8 and Gata4 in the mouse, the phenotypic penetrance 
of this interaction is very weak and I was unable to identify a clear cause of death in these 
animals.  Given that the Kahn lab focuses on mammalian cardiovascular development, it 
is unlikely that we will continue to study Atoh8.  However, I have identified two potential 
future directions that may be of interest to other groups: 1) determining the mechanism 
through which zebrafish atoh8 regulates cardiac development, and 2) possible functions 
of Atoh8 in adult mammals. 
 
The role of atoh8 in the zebrafish heart 
 My morpholino gene suppression studies clearly show that zebrafish heart looping 
is dependent on Atoh8.  I did not, however, identify molecular targets or pathways that 
were disrupted in the morphant hearts.  Heart looping defects have been linked to 
multiple causes, including disruption of cardiac transcription factors (23,34,61,63,90), 
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cardiac ion channels (91) and cardiac structural proteins (92).  Given the robust synergy 
we observe between Atoh8 and Gata4-Fog1 (Figure 2.3), there is likely a shared 
mechanism between Atoh8 and these other genes in regulating heart looping.  
Unfortunately, the studies to date in the zebrafish have not identified the targets of Gata4 
(23) or Fog1 (34) in heart development, so there are no clear candidates.  I therefore 
propose examining the expression pattern of multiple developmental cardiac transcription 
factors such as hand2, tbx5a, mef2c, gata5 and nkx2.5 by in situ hybridization in order to 
determine if the specification of cardiomyocyte progenitors is preserved in atoh8, gata4, 
and zfpm1 (Fog1) morphant embryos.  I would propose further examination of the 
expression of cardiac structural proteins such as cardiac actin and myosin genes to 
determine whether proper development from progenitor to differentiated cardiomyocyte 
is preserved.  Given the lack of cardiac defects in Atoh8 mutant mice, it is unlikely that 
these processes are conserved into mammals.  However, these studies may reveal how 
these factors contribute to heart looping and also may provide insight into how Atoh8, 
Gata4, and Fog1 interact. 
 
A possible role for Atoh8 in the adult iron metabolism 
 Although my studies showed that Atoh8 is not required for development and 
survival, the high degree of conservation in ATOH8 sequence suggests evolutionary 
pressure to preserve this protein and argues for some role for Atoh8 in mammals.  Given 
the lack of a requirement for Atoh8 in the embryo, it is plausible to infer that the 
requirement for Atoh8 may be limited to the adult animal.  Such requirements may be 
difficult to observe in adult mice in the laboratory setting, particularly if Atoh8 is required 
 89 
in stress responses that a laboratory mouse may be unlikely to encounter.  Based on my 
work here and previously reported studies on Atoh8, I propose studying the potential 
Atoh8 function in the regulation of iron metabolism in the adult liver. 
 Iron metabolism is regulated by multiple inputs, such as hepatic and circulating 
iron levels, erythropoietic activity, and inflammation (93).  In the liver, excess iron levels 
are detected by an unknown sensor, which increases hepatic production of BMP6 (94).  
BMP6 increases production of hepcidin, a regulatory protein that inhibits iron absorption 
and iron export from the intestine and promotes sequestration of iron within 
reticuloendothelial macrophages (93).  Atoh8 has been shown to be upregulated in the 
mouse liver following excess iron accumulation secondary to either dietary iron overload 
or genetic deletion of hepcidin (95), indicating that Atoh8 may be part of the hepatic 
response program to iron overload.  Hepatic Atoh8 expression is also dependent on 
BMP6-Smad4 signaling (95), suggesting that Atoh8 may be a direct target of this 
signaling pathway.  The mutant mice models we have generated for the Atoh8 project are 
ideally suited for testing the requirement for ATOH8 in iron metabolism.  I propose 
examining the hepatic and circulating iron levels in adult Atoh8Δex1/Δex1 mice vs. control 
littermates, on both a normal chow diet and an iron-enriched diet.  If differences in iron 
levels are observed in ATOH8-deficient animals, I propose examining the levels of 
hepcidin and BMP6 to attempt to determine the mechanism by which ATOH8 affects 
iron regulation.  Intriguingly, a previous report identified GATA4 as a transcriptional 
regulator of hepcidin (96); it is possible that the genetic and physical interactions I have 
identified between ATOH8 and GATA4 in my work may be applicable in the context of 
iron regulation. 
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Future Directions: MEKK3 
 Our studies here have clearly shown that MEKK3 can interact with CCM2L and 
regulate its function, and have also demonstrated that MEKK3 has a required role in the 
endocardium that is very similar to the role of HEG and CCM2L in this tissue.  Future 
studies are now needed to further characterize the defects in Nfatc1Cre Map3k3fl/- mice, to 
identify the factors upstream and downstream of MEKK3 in the endocardium, and to 
investigate the role of other CCM proteins in the endocardium in development. 
 
Characterizing the defect in Nfatc1Cre Map3k3fl/- mice 
 My experiments with the Nfatc1Cre Map3k3fl/- mice demonstrate that embryonic 
lethality at E11.5 and severe myocardial thinning result from endocardial loss of 
MEKK3.  This phenotype is remarkably similar to the phenotype previously reported by 
our lab in Heg-/- Ccm2l-/- embryos (58).  Future experiments are needed to fully 
characterize the Nfatc1Cre Map3k3fl/- phenotype to determine why endocardial loss of this 
protein results in a myocardial defect.  First, we need to determine why there is a 
decrease in myocardial tissue—is this a decrease in proliferation, or an increase in 
apoptosis?  We will use bromodeoxyuridine (Brdu) pulse labeling and TUNEL staining 
to determine the respective rate of proliferation and apoptosis in the endocardium and 
myocardium of Nfatc1Cre Map3k3fl/- hearts.  Preliminary immunostaining suggests that 
proliferation is reduced within the myocardium of these animals with no changes in 
endocardial proliferation or in apoptosis in either tissue (data not shown), which would 
agree with the reported result in Heg-/- Ccm2l-/- embryos.   Additional analysis is needed 
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to quantify this proliferative change to confirm that there is a significant change in 
Nfatc1Cre Map3k3fl/- hearts. 
 Following my studies on proliferation and apoptosis, I propose to examine how 
loss of endocardial MEKK3 leads to myocardial defects.  Given the physical separation 
between the endocardium and myocardium at E10.5-11.5, it is reasonable to conclude 
that there is a deficiency in a secreted endocardial factor.  In the study of Heg-/- Ccm2l-/- 
embryos, the decreased myocardial growth was attributed to a decrease in endocardial 
FGF16 transcription (58), which had previously been shown to be required for 
myocardial growth (45,59).  It is therefore reasonable to start with FGF16 and the related 
factors FGF9 and FGF20 as initial candidates.  However, myocardial growth has been 
shown to be dependent on multiple growth factor signals in addition to FGFs, such as 
neuregulin (43) and Notch (97).  I would therefore like to do transcriptional profiling of 
whole E10.5 Nfatc1Cre Map3k3fl/- hearts to screen for changes in multiple signaling 
pathways.  If I am able to identify a signal as a plausible cause for the defects in Nfatc1Cre 
Map3k3fl/- hearts, I will attempt to rescue the defect using heart explant cultures.  In these 
experiments, explanted hearts are cultured with replacement cytokines to rescue a 
proliferation defect; this technique has previously been used to rescue hearts deficient in 
FGFs (98) or neuregulin (97) to link proliferation specifically to deficits in these 
endocardial growth factors. 
 
Identifying the pathways downstream of MEKK3 
 MEKK3 is a MAPK kinase kinase kinase and has no known transcriptional 
activity; it is likely that there are downstream targets of MEKK3 within the enodcardial 
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cell that convey a signal that ultimately promotes increased transcription of growth factor 
genes.  Although the in vivo endothelial targets of MEKK3 have not been identified, 
MEKK3 has been shown to be upstream of the MAPK kinases ERK5 and p38 in cultured 
endothelial cells (99).  In immune cells, where it has been studied more extensively, 
MEKK3 has been shown to have additional roles as an upstream activator of the MAPK 
kinase JNK and also as an activator of NF-ΚB pathway (100).  These pathways are our 
best candidates for possible downstream targets of MEKK3 in the endocardium.  We 
propose three approaches to identifying which target pathway is critical in these cells.  
First, we will examine the phosphorylation of MAPK and NF-ΚB pathway components 
in E10.5 Nfatc1Cre Map3k3fl/- hearts to screen for decreased activation of these pathways 
with endocardial loss of MEKK3.  While this approach allows me to look directly at the 
in vivo situation, it is potentially complicated by the small number of cells in an E10.5 
heart, which would limit omy source material, and by the presence of non-endocardial 
cells (primarily myocardium), which may have phosphorylated MAPK proteins and mask 
changes in the endocardium.  To address the latter concern, I could attempt to sort 
endocardium from these hearts to isolate a pure population, although I would still be 
limited by the number of endocardial cells. 
 In addition to investigating phosphorylation in vivo, I will also use our adenoviral-
CCM2L HMVEC expression system (Figure 3.2) to identify possible MEKK3 targets.  In 
this system, overexpression of CCM2L increases FGF16 transcription.  Suppression of 
MEKK3 with siRNA inhibits this increase, indicating that CCM2L is likely acting 
through MEKK3 and suggesting that this cell culture system may be a somewhat similar 
model of the in vivo pathway in the endocardium.  I will use siRNA against potential 
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targets of MEKK3 in the endocardium in order to identify which proteins are required for 
this CCM2L-induced upregulation of FGF16 levels. 
 Finally, I can ablate candidate genes in the endocardium using the Nfatc1Cre allele 
and screen for phenotypes similar to the Nfatc1Cre Map3k3fl/- mouse.  This approach is the 
best tool for confirming that the candidate is truly operating in the same path as MEKK3; 
however, the large number of possible candidates precludes pursuing this approach on a 
large scale and I will therefore limit this approach to our most likely candidates.  At this 
point, I plan to pursue this approach with the MAPK kinase ERK5; I suspect ERK5 
because it has been shown regulated by MEKK3 in the endothelium (99), and because 
endothelial-specific ERK5 mutants are highly similar to MEKK3 mutants (85,101).  If 
my other approaches identify other MAPK and NF-ΚB pathways as being better 
candidates than ERK5, we will make endocardial deletions of those genes. 
 
Identifying the upstream activator of MEKK3 
 In addition to identifying the downstream targets of MEKK3 in the endocardium, 
I would like to identify potential upstream signals that activate MEKK3, presumably 
through an activating phosphorylation of MEKK3.  Although HEG and the CCM proteins 
genetically and/or physically interact with MEKK3, none of these proteins have intrinsic 
kinase activity and therefore would be unable to directly activate MEKK3.  In order to 
identify potential activators of MEKK3, I will attempt to detect proteins that physically 
interact with MEKK3 and the HEG/CCM complex, which I hypothesize may interact 
with MEKK3 in the endocardium.  I will create a lentiviral construct expressing FLAG-
HA-HEG or FLAG-HA-MEKK3 in a doxycycline-inducible manner.  I will use this 
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lentivirus to express tagged proteins in endothelial cells such as HMVECs, and then 
titrate the level of expression to endogenous levels via the doxycycline-inducible system.   
I will then immunoprecipitate the tagged proteins via their double epitope tags, and 
perform mass spectrometry to identify binding partners of HEG and MEKK3. 
 As an alternative to the traditional immunoprecipitate mass spectrometry 
approach, I am also using a recently reported biotin-labeling strategy to identify HEG and 
MEKK3 interactors (102).  In this approach, a mutated promiscuous biotin ligase is fused 
to the protein of interest.  The biotin ligase biotinylates other proteins in the vicinity of 
the fusion protein; interacting proteins should be enriched when biotinylated proteins are 
immunoprecipitated from the cell lysate.  This approach is particularly attractive for 
identifying HEG interactors, as the lysis conditions necessary to liberate HEG from the 
cell membrane may disrupt protein-protein interactions, whereas a biotin-tag should be 
permanent even if interactions are disrupted by lysis.  However, there may be more 
background noise with this approach, as non-interacting proteins in the same subcellular 
domain as HEG or MEKK3 may also be labeled. 
 
Determining the endocardial functions of CCM proteins 
 My studies with the Nfatc1Cre Map3k3fl/- mouse revealed a clear requirement for 
MEKK3 in the endocardium that had been previously been hidden by the early 
embryonic death imposed by vascular defects in constitutive and endothelial (Tie2Cre) 
deletions of this gene.  I would like to pursue a similar approach with CCM1 and CCM2.  
Global and endothelial-specific mutants of CCM1 and CCM2 are lethal at E9.5 due to 
defects in development of the branchial arch arteries (54,55).  This results in a failure to 
 95 
connect the heart outflow tract with the descending aorta, which prevents effective 
circulation.  My lineage trace experiments show that Nfatc1Cre expression is not present 
in the branchial arch arteries (Figure 3.3), indicating that deletion of CCM1 or CCM2 
with this Cre allele should bypass this early lethal vascular defect.  I will generate 
Nfatc1Cre Krit1fl/fl and Nfatc1Cre Ccm2fl/fl to delete CCM1 and CCM2, respectively, in the 
endocardium.  Preliminary results showing an absence of viable Nfatc1Cre Krit1fl/fl 
animals at birth (Table 3.3) indicate that CCM1 is required at some point in the 
endocardium in embryogenesis; timed matings are needed to determine when and why 
these animals die.  I will pursue similar crosses with the Ccm2fl allele to determine the 
requirement for CCM2.  It is possible that CCM2 may be redundant with its paralogue 
CCM2L, which is expressed in the embryonic endocardium (58).  To account for this 
possibility, I will also examine Nfatc1Cre Ccm2fl/fl Ccm2l-/- double mutant animals.  If 
MEKK3 interacts with CCM1 or CCM2 in the endocardium, it is possible that the 
endocardial deletions of CCM1 or CCM2 will phenocopy endocardial deletion of 
MEKK3.  Alternatively, I may see other defects within the endocardium, or lethal defects 
in the development of the coronary endothelium that is arises from endocardium in later 
embryogenesis (Figure 3.3). 
 
Concluding remarks 
 Our studies of ATOH8 clearly define the requirements for ATOH8 between 
different vertebrate species.  While there is a requirement for atoh8 in the developing 
zebrafish heart, our Atoh8 null mice definitively demonstrate that this requirement is not 
preserved in mammalian development.  In a similar manner, the robust genetic interaction 
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we observe between Atoh8 and Gata/Fog proteins in the zebrafish development is much 
reduced in the mouse.  Further studies will be needed to determine if and where ATOH8 
may function in the adult mammal, and to determine whether ATOH8 interacts with 
GATA or FOG factors in these processes outside of development. 
 Our studies of MEKK3 indicate that this kinase has a critical role in the 
endocardium to facilitate myocardial growth, likely by promoting growth factor 
production.  This finding provides a mechanism to explain the phenotype that was 
observed in HEG-CCM2L double mutant mice, and identifies a role for MEKK3 in the 
endocardium that had previously been masked by the early lethal vascular defects of prior 
deletions of this gene.  Future studies are needed to define the upstream activators and 
downstream targets of MEKK3 within the endocardium, and to further define the 
functions and interactions of the HEG-CCM-MEKK3 complex within the endocardium 
and within the remainder of the endothelium. 
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